Stockwinners Market Radar for January 19, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST Cathie Wood's ARK Investment bought 193.5K shares of Blade Air Mobility today

20:04 EST Olin announces reduction of bleach capacity - Olin announced that it will discontinue bleach manufacturing at its Tracy, CA facility by June 30, 2022.

19:01 EST Hutchmed initiates Phase I trial of HMPL-653 in China - Hutchmed announced that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-653 in the treatment of patients with advanced or metastatic solid tumors and tenosynovial giant cell tumors. Approximately 110 patients are expected to be enrolled in the dose escalation and expansion phase of this study. The primary endpoints are dose limiting toxicity, safety, tolerability, recommended phase II dose and maximum tolerated dose. The secondary endpoints include pharmacokinetics, objective response rate, progression free survival, disease control rate, and overall survival. The lead principal investigator is Dr Cheng Ying of the Jilin Cancer Hospital, which is the lead institution for this study.

18:23 EST SoFi Technologies CEO: Our goal is to be a one-stop shop for all financial needs - In an interview on CNBC's Mad Money, Anthony Noto said getting regulatory approval to become national bank was a "huge milestone" for SoFi. The company can give more back to the consumer since its cost base is lower, he noted. It will be able to offer more loans at lower interest rates with the new bank charter. He added that SoFi is "absolutely going after" legacy bank accounts connected to the FDIC.

18:02 EST Yalla announces dismissal of securities class action lawsuit - Yalla Group announced that the lead plaintiffs in a securities class action lawsuit against the company and its CEO voluntarily dismissed the lawsuit on January 12, which marks a successful and final conclusion of the lawsuit for the company. The lawsuit arose from certain short-seller reports issued in May 2021 that contained numerous errors as well as distorted, misleading and unsubstantiated claims regarding the company. While the company publicly refuted the claims in the short-seller reports, a putative securities class action lawsuit was filed against the company and its CEO in the United States based on the claims in the short-seller reports, claiming that the company had violated U.S. securities laws. The U.S. court presiding over this lawsuit ordered the lead plaintiffs and their attorneys to file an amended complaint by January 7. After several months of preparation, the lead plaintiffs and their attorneys failed to file an amended complaint by the deadline set by the court. Instead, the lead plaintiffs and their attorneys elected not to further pursue this lawsuit and voluntarily dismissed the lawsuit on January 12, agreeing to bear their own litigation costs. Lead plaintiffs are barred from refiling the same claims. The voluntary dismissal equally applies to all claims asserted against the company's CEO, who was named a co-defendant in the lawsuit. The court approved the lead plaintiffs' voluntary dismissal on January 13, and the lawsuit is terminated. Throughout the process, the company maintained that the lawsuit had no factual basis. The company believes the decision of the lead plaintiffs and their attorneys to voluntarily dismiss all of their claims after several months of preparation supports the company's position that claims in the short-seller reports are groundless.

17:54 EST Omeros submits response to FDA on narsoplimab BLA - Omeros submitted to the FDA earlier this month its response to the Agency's Complete Response Letter for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. The response comprises a comprehensive briefing package drafted in close collaboration with external clinical, regulatory and legal experts that addresses in detail the points raised by FDA in its CRL for narsoplimab. Omeros concurrently requested a Type A meeting with FDA to resolve any outstanding items. Narsoplimab is the first drug candidate submitted to FDA for approval in HSCT-TMA. It has Breakthrough Therapy and Orphan designations in both HSCT-TMA and IgA nephropathy.

17:33 EST Alerus Financial boosts dividend 6.7% to 16c per share - Alerus Financial announced that its board of directors declared a regular quarterly cash dividend of 16c per common share, a 6.7% increase over the dividend paid a year ago. The dividend is payable on April 8, to shareholders of record as of close of business on March 18.

17:03 EST Parsons awarded $11M contract by DARPA for ground operations center - Parsons was awarded an $11M sole-source contract in December 2021, to plan, standup, and demonstrate a prototype ground operations center in support of Defense Advanced Research Project Agency's - DARPA - Blackjack flight demonstration activities. The new contract is a follow-on to a phase II small business innovation research contract won by Braxton Technologies prior to Parsons' 2020 acquisition of the software company. Parsons will develop and demonstrate the ground operations center plan, perform mission planning, execute flight operations, and design and configure the operations facility to support satellite demo mission operations, including orbit monitoring, maneuvering, vehicle health and status, and other flight operations requirements. The company will also deliver end-to-end network connectivity between the GOC and commercial ground station providers, enabling global coverage for the Blackjack mission.

16:57 EST Warren Buffett's MidAmerican Energy discloses $3.9B Iowa wind and solar plans - MidAmerican Energy announced plans for a $3.9B renewable energy project in Iowa, including wind and solar generation, and the exploration of new technologies to advance the company's transition to net-zero greenhouse gas emissions. In a filing with the Iowa Utilities Board, MidAmerican's proposed project, called Wind PRIME, would add 2,042 megawatts of wind generation and 50 megawatts of solar generation. The company also proposed conducting feasibility studies focused on other clean generation technologies, including carbon capture, energy storage and small modular nuclear reactors....MidAmerican Energy, a subsidiary of Warren Buffett's Berkshire Hathaway Energy, is headquartered in Des Moines, Iowa. Reference Link

16:49 EST Omega Flex names Dean Rivest president - Omega Flex announced that it has evaluated the future short- and long-term needs for the success of its business at the senior levels of the organization. Dean W. Rivest has been appointed as President of the company, reporting directly to Mark F. Albino, who has retained the position of chief operating officer of the company. Edwin B. Moran has been appointed as Executive Vice President of Sales, including all industrial and commercial products, reporting to Mr. Rivest. Matthew F. Unger has been appointed as Vice President - Finance and Chief Financial Officer, reporting to Mr. Rivest. Kevin R. Hoben, Chairman and CEO of the company, stated "This segregation of duties at the highest executive level in the organization allows Omega Flex to laser focus on the most critical short-term needs currently challenging our business while positioning the Company for continued success in achieving its long-term goals."

16:43 EST Enviva Partners signs MOU to develop supply chain strategy for fuels - Enviva announced the signing of an MOU with a U.S.-based cleantech company to co-develop a supply chain strategy for advanced, low-carbon transportation fuels, including sustainable aviation fuel, or SAF, with a focus on the customer's operations in the U.S. Southeast and potentially California. Under the MOU, the customer's refining process will convert Enviva's woody biomass into a drop-in replacement for crude oil used for producing aviation fuel. Enviva's current operations and numerous potential development sites in the U.S. Southeast position it to co-develop alongside the SAF refining capacity the customer intends to construct in the region. California is another jurisdiction where Enviva is evaluating plans to build one or more facilities with the intent of utilizing low-grade wood fiber from high-hazard zones in the state both to mitigate devastating wildfire risk in the region and tackle the negative effects of climate change globally. This latest MOU represents not only the second industrial agreement Enviva has recently signed, but also Enviva's second agreement related to SAF, which the company believes underscores the demand momentum for low-carbon transportation fuels. The company said, "We recently announced our first shipment to Germany to serve its emerging industrial market (including steel and cement) and other adjacent use cases (such as lime, a key input in cement manufacturing) that are progressing through the phases of design, development, and application, as industrial companies pursue not only their own net-zero goals, but also fulfill the increasing demand for greener products from their own customers. As of January 1, 2022, Enviva's total weighted-average remaining term of executed long-term take-or-pay off-take contracts is approximately 14.5 years, with a total contracted revenue backlog of over $21 billion. This contracted revenue backlog is complemented by a customer sales pipeline exceeding $40 billion, which includes contracts in various stages of negotiation. Enviva's customer sales pipeline consists of the U.S.-based MOU, the previously announced J-Power MOU, and other long-term off-take opportunities in our traditional markets for biomass-fired power and heat generation in geographies ranging from the United Kingdom to the European Union (including emerging opportunities in Germany and Poland), to Asia (including incremental demand in Japan, emerging potential in Taiwan, and maturing opportunities in South Korea), as well as in developing industrial segments across the globe (including steel, cement, lime, chemicals, SAF, and biodiesel). We are negotiating long-term wood pellet supply contracts with several leading industrial companies in each of these difficult-to-abate sectors that are actively and urgently pursing large-scale decarbonization. Over the next 12 months, we expect to progress negotiations and convert several sales pipeline opportunities into binding contracts, including MOUs."

16:36 EST Air Industries wins two LTAs for Blackhawk Helicopters worth $18.2M - Air Industries Group announced that its Long Island-based subsidiary, Air Industries Machining Corp., has been awarded two separate Long-Term Agreements to manufacture flight-critical assemblies for the Blackhawk helicopter. The estimated value of the two LTAs will total approximately $18.2M over their five-year terms. The agreements include a five-year LTA to manufacture the primary flight control assembly for the Blackhawk helicopter, with an estimated life-of-the-contract value of $9.9M. The second five-year LTA, to produce a flight critical component for the same aircraft, has an estimated life-of-the-contract value of $8.3M.

16:34 EST Phillips 66, Novonix sign lithium-ion battery development agreement - Phillips 66 and Novonix have signed a technology development agreement to advance the production and commercialization of next-generation anode materials for lithium-ion batteries. Phillips 66 became a major investor in Novonix in September 2021, when it acquired a 16% stake in the company. The investment is supporting Novonix's growth as it scales up production and develops new technologies for higher-performance energy storage applications. Phillips 66 and NOVONIX will leverage existing intellectual property and R&D capabilities to drive commercial development of optimized feedstocks and lithium-ion anode materials with reduced carbon-intensive processing. Phillips 66 is a global manufacturer of specialty coke, a precursor to the synthetic graphite anode material Novonix produces. Novonix's anode materials business is based in Chattanooga, Tennessee.

16:31 EST KemPharm issues letter to shareholders regarding clinical development strategy - KemPharm announced that Travis Mickle, president and CEO of KemPharm, has issued a letter to shareholders detailing the company's strategic focus on Central Nervous System, or CNS/Rare Disease indications, as well as an updated clinical development strategy. The letter said, "Today is an important milestone in the ongoing evolution of KemPharm and follows a series of transformative events for the company during the past 12 months highlighted by the U.S. commercial launch of AZSTARYS(R), the uplisting of our stock to the Nasdaq Global Select Market and its addition to the Nasdaq Biotechnology Index, and the restructuring and recapitalization of our finances, culminating with the announcement of a $50 million share repurchase program through 2023. These events have allowed us to build a strong foundation for the Company's future, and with that momentum, we have worked to thoughtfully refine our strategic focus to CNS/Rare Disease indications for our future product development efforts. Given our significant expertise and a track record of product development success, our strategic focus on CNS/rare disease indications allows us to target high-value areas with significant unmet needs. Our evaluation of both internal and external product candidates is guided by criteria that include an assessment of the commercial opportunity, and understanding of clinical, development and regulatory risks, as well as time, cost and need, among other strategic considerations. Within CNS/rare disease, there are many potential indications where we believe our LAT(R) (Ligand Activated Therapy) platform technology and our product development expertise can provide multiple opportunities to drive growth for KemPharm. Some of the possible areas of interest include: Neurology and neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and Huntington's disease;Psychiatric disorders, which could include indications focused on niche market opportunities like rare sleep disorders or psychedelics; and Rare diseases and other adjacent or related therapeutic categories, like gastroenterology, metabolic diseases or endocrinology... Given these factors, we see a substantial opportunity to advance KP1077 as a treatment for IH, and initial market research suggests that KP1077 could capture a large share of the IH market based on the following potential treatment, regulatory and commercial benefits: Dosing flexibility - either one dose or two doses - designed to address the two primary issues associated with IH: Nighttime dose would address sleep inertia. Morning dose would address daytime brain fog. No drug-drug interaction potential especially with hormonal contraceptives and antidepressants. Reduced abuse potential with a Schedule IV designation. Orphan drug designation potential, as well as fast-track and breakthrough designation eligibility. No generic equivalent. Composition of matter patents extending to 2037 with additional applications potentially extending the IP time horizon. In addition to these potential benefits, we anticipate an efficient and robust development program for KP1077. At present, we are targeting an Investigational New Drug (IND) application filing for KP1077 in IH by mid-year 2022. We then anticipate initiating a Phase 2 trial of KP1077 in IH in the third quarter of 2022 with top-line data by the second quarter of 2023. We are also planning a parallel development program for KP1077 in narcolepsy. The IND filing for this additional program is expected during the second half of 2022, with a Phase 2/3 trial expected to begin by the end of 2022 or early 2023. While KP1077 will be our lead SDX development candidate, we plan to continue the development of KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD). However, through our evaluation of the clinical, regulatory and development risks for pursuing the SUD indication, we recognized that KP879 will require a more challenging and lengthier development program that will likely necessitate partnership with government, academia, or other strategic partners to successfully advance the program toward approval..."

16:28 EST FAA says certain Boeing 777 aircraft cleared to fly to airports with 5G C-band - The FAA has issued new approvals that allow an estimated 62% of the U.S. commercial fleet to perform low-visibility landings at airports where wireless companies deployed 5G C-band. The new safety buffer announced Tuesday around airports in the 5G deployment further expanded the number of airports available to planes with previously cleared altimeters to perform low-visibility landings. The FAA early Wednesday cleared another three altimeters. Even with these approvals, flights at some airports may still be affected. The FAA also continues to work with manufacturers to understand how radar altimeter data is used in other flight control systems. Passengers should check with their airlines for latest flight schedules. Airplane models with one of the five cleared altimeters include some Boeing (BA) 717, 737, 747, 757, 767, 777, MD-10/-11 and Airbus (EADSY) A300, A310, A319, A320, A330, A340, A350 and A380 models.

16:25 EST Google says G Suite legacy free users need to sign up for paid subscriptions - Alphabet's Google said that users who have the G Suite legacy free edition need to upgrade to a paid Google Workspace subscription to keep their services. The G Suite legacy free edition will no longer be available starting July 1, 2022. The company said that, in order to maintain services and accounts, users need to upgrade by May 1, 2022. "After you upgrade you can use your new subscription at no cost until at least July 1, 2022," the company said. "If you choose to wait, Google will begin upgrading subscriptions automatically on May 1, 2022. We will upgrade your organization to a new Google Workspace subscription based on the features you currently use." Reference Link

16:19 EST Greif anounces price incerases on several products - Greif is implementing a $50 per ton price increase for all grades of uncoated recycled paperboard and a minimum 6.0% increase on all tube and core and protective packaging products. The uncoated recycled paperboard increase is effective with new orders and shipments on and after February 14. The tube and core and protective packaging products increase is effective with shipments on and after March 4. These price increases are in response to strong demand across the Greif paperboard and converting network and inflationary cost increases in energy, labor, transportation, maintenance, chemicals and other raw materials.

16:17 EST KKR acquires Merchants Mortgage Trust & Corporation - KKR announced that KKR has acquired Merchants Mortgage Trust & Corporation, a real estate lending platform specializing in short-term mortgage products for experienced individual residential real estate investors. KKR is making its investment in MMTC through its private credit funds and accounts as part of the firm's Asset-Based Finance investment strategy, which pursues privately originated investments backed by diversified pools of hard and financial assets. MMTC's Chief Executive Officer, Justin Land, and the existing management team will continue to lead the Company. KKR's investment provides MMTC with access to long-term capital to grow its origination activity and support the expansion of its product offerings, geographic footprint and financing capabilities. As a part of this transaction, MMTC will also acquire the outstanding interests in its affiliate, Orchard Funding. Financial terms of the transaction were not disclosed.

16:13 EST Casper Sleep announces stockholder approval of merger agreement - Casper Sleep announced that its stockholders voted today to adopt the Agreement and Plan of Merger, whereby Casper will be acquired by certain subsidiaries of Durational Consumer SPV IV, LP, an investment vehicle managed by Durational Capital Management, LP. According to the preliminary results announced at Casper's Special Meeting of Stockholders, approximately 69.5% of the vote represented by Casper's outstanding stock were voted in favor of the Merger Agreement. The final voting results of the Special Meeting, as tabulated by an independent inspector of elections, will be filed as part of Form 8-K with the U.S. Securities and Exchange Commission. Subject to the satisfaction of certain other closing conditions, the transaction is expected to close during the week of January 24, 2022. Upon closing the transaction, Casper will operate as a privately-held company and will remain based in New York.

16:09 EST Circor's Scott Buckhout to step down as CEO - CIRCOR International announced that the Board of Directors and Scott Buckhout, President and CEO, have mutually agreed that Mr. Buckhout will step down as President and CEO, effective immediately. The Board also announced that Aerospace & Defense Group President Tony Najjar has been promoted to COO and named interim President and CEO. The Company has selected a leading executive search firm to identify a permanent President and CEO.

16:07 EST National Retail Properties CEO Julian Whitehurst to retire on April 28 - National Retail Properties announced that Julian Whitehurst, President and CEO, will retire and step down as a member of the Board of Directors effective April 28. Stephen Horn, Jr., currently Executive Vice President and COO, will assume the role of President and CEO as of April 29.

16:01 EST DXC Technology expands global partnership with ServiceNow - DXC Technology (DXC) announced the formation of a new global DXC ServiceNow Strategic Business Group to deliver market-leading, cost-efficient, resilient technology services that transform enterprise service operations, built on DXC Platform X. DXC has named ServiceNow (NOW) the preferred workflow partner for DXC Platform X, a data-driven, intelligent automation platform that helps detect, prevent and address issues before they happen with resilient, self-healing IT estates. NelsonHall has named DXC Platform X as a "Leader in Cognitive & Self-Healing IT Infrastructure Management," reflecting DXC's ability to deliver immediate benefits through automation while meeting customer requirements for their future operating models. "For our customers, it's about modernizing and automating their IT estates to achieve a state of 'silent operations,' saving time, money and letting customers focus on what's most important --- running their business," said Mike Salvino, President and CEO, DXC Technology. "We manage complex IT estates on DXC Platform X and building on this unique strength with ServiceNow will establish us as a clear market leader in the enterprise service management market."

14:29 EST Sorrento reports 1M COVISTIX tests distributed last week in Mexico - Sorrento Therapeutics and Sorrento Mexico announced that approximately 1,000,000 COVISTIX tests were distributed last week in Mexico. "Orders are increasing daily as pent-up demand is high for a sensitive and convenient test that is capable of accurately detecting all of the current variants of the SARS-CoV-2 virus, including the dominant Omicron variant. Millions of additional COVISTIX tests are scheduled to be delivered to Mexico, with tens of millions more being manufactured to support the increasing demand for COVISTIX worldwide," the company stated in a press release. "We believe there is a significant unmet need for a sensitive and rapid antigen test which detects Omicron with high sensitivity even for asymptomatic patients," added Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.

14:07 EST Sangamo CEO says partnerships bring validation to company's technology - Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, CEO Sandy Macrae discussed the company's partnerships: "We're always speaking with people about our technology. We think they find Sangamo's technology intriguing and when they spend time with our scientists, they find it exciting. For us, it's a balance we always have to find on whether we develop something ourselves or with a partner. Our partnerships bring expertise. Biogen [BIIB] really understands Alzheimer's with their biologists and physicians, and they have the commercial team to make a success of the medicine. It's not only about money but also about expertise. They also bring the validation of our technology, that they looked at what we were doing and decided that they were going to invest this much money says that there was something solid about it. Some deals have a natural time stamp to them. The Novartis [NVS] work is almost completed and we completed much of the work we were doing for Pfizer [PFE]. But they've come back and often try to find things they can do to continue the partnership. We usually survey our partners and in the recent survey we did, our partners look at us as the best or one of the best partners they have," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

13:59 EST Sangamo CEO says preclinical studies moving forward 'beautifully' - Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, CEO Sandy Macrae talked about the company's preclinical studies: "Everything is moving forward beautifully. Until we get to the IND, we tend to keep the cards close to our chest on the benefits of our programs. But related to the TX200, which is the renal transplant subject, we have TREG programs being developed in multiple sclerosis for example. In our CNS portfolio, we have very interesting assets in important neurological diseases moving forward and closer to clinic. We will publish results on them during the year. It takes time. We're an unusual company with such a broad and deep portfolio, and a pipeline that keeps on giving and it's all due to our technology which can be applied to so many areas of unmet medical need. And we also have our partnerships with Biogen [BIIB] for Alzheimer's and Parkinson's disease, which is making great progress; our work we are doing with Novartis [NVS] on Autism spectrum disorder, which again is moving forward; with Takeda [TAK] for Huntington's; and with Kite [GILD] and their oncology program. They are all moving forward and getting closer and closer to the IND, which is when investors and analysts really start getting interested in it," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

13:49 EST EXL appoints Jennifer Lemming as CMO - EXL announced the appointment of Jennifer Lemming as Chief Marketing Officer. Charged with accelerating EXL's data-driven transformation agenda, Lemming will help marshal the company's advanced analytics, AI, digital and cloud capabilities to unlock new growth opportunities for the world's leading corporations. Lemming joins EXL from LexisNexis Risk Solutions, a RELX company, where she was Senior Vice President, Marketing.

13:38 EST Instagram introduces Subscriptions, 'newest monetization feature' for creators - Instagram said in a blog post: "At Meta, we strongly believe in enabling creators to make a living through our platforms and have built a suite of tools to allow them to do that-helping them get support from their audience, partner with brands and earn money from advertising or bonuses directly from Instagram and Facebook. We're excited to introduce our newest monetization feature: Instagram Subscriptions. In 2020, Facebook launched Subscriptions, which has helped creators build sustainable businesses powered by the support of their communities. Based on strong creator feedback, we're ready to now bring this business model to creators on Instagram. With Instagram Subscriptions, creators can develop deeper connections with their most engaged followers and grow their recurring monthly income by giving subscribers access to exclusive content and benefits, all within the same platform where they interact with them already... Earlier this year, as part of our continued commitment to supporting creators, we shared that Meta would not collect any fees from creators on Facebook Subscriptions purchases until 2023 at the earliest, and this will also apply to Instagram Subscriptions. Additionally, we believe that creators should know their audience and have more control over their business. We hope to build the tools to allow them to also directly connect with their audience off platform in the future." Reference Link

13:30 EST Sangamo tells Fly 'not immune' to COVID-related impacts, but 'mostly on track'

13:30 EST Sangamo expects to dose first patients by mid-2022 in TX200 trial, COO says

13:30 EST Success in CAR-TREG more than just science, Sangamo CEO says

12:46 EST Voss Capital: Second director nominee for Griffon board has had to withdraw - Voss Capital, LLC, a significant shareholder of Griffon Corp., announced that another of its director nominees has informed Voss that he must withdraw from the proxy contest at Griffon due to a sudden reversal of approval from his employer. Voss issued the following statement: "Voss initiated this proxy fight only after repeated efforts to collaborate privately with the Company, as is always our preference. It was only after Griffon's management continually refused to acknowledge the clear need for change that we resorted to a public contest and nominated highly qualified candidates to finally bring independent oversight to Griffon's Board. We believe our efforts have been well received by shareholders, many of whom may have been hoping to support both of our candidates. With two of our three director nominees being forced to withdraw under similar, questionable circumstances, we feel the need to publicly express our growing concern that such reversals may have been influenced by Griffon executives or directors, or third parties acting under their direction. The highly unusual rescinding of nomination permission from the separate employers of both our candidates leads us to question whether the circumstances are truly coincidental. In each case, the nominee's employer initially approved of the nominee's participation in this contest, only to reverse their decision and revoke approval later in the process... We would urge Griffon's Board to immediately investigate these matters to determine whether anyone from Griffon was involved with these nominee withdrawals. We would be pleased to comply with these efforts to the best of our ability. It is clear to us that the Company is concerned that every day more shareholders are being swayed by our strong case for change and plan for value creation. Is Griffon's management so threatened by even a single dissenting voice in the Boardroom that they would seek to deny shareholders their right to vote on independent Board representatives?"

12:33 EST Disney reports 179M subscriptions across Disney+, ESPN+, Hulu at end of FY21 - "Disney's direct-to-consumer efforts have progressed at a tremendous pace in just a few short years, and our organization has continued to grow and evolve in support of our ambitious global streaming strategy," CEO Bob Chapek said. "Rebecca has played a vital role in orchestrating our global platform expansion, and I'm excited that she will be leading our new International Content group, bringing her expertise and talent to oversee the growing pipeline of original local and regional content for our streaming services while continuing to lead our international operations. Likewise, with a relentless focus on serving consumers, Kareem has developed an industry-leading team of seasoned executives who are uniquely equipped to take our streaming business into Disney's next century."

12:15 EST DSS acquires 25.1% of Alset International - DSS entered into a stock purchase agreement on January 18, 2022, with its shareholder Alset EHome International Inc., which currently owns 15.24% of the company's outstanding shares of common stock, pursuant to which AEI sold to the company 877,248,065 ordinary shares, no par value per share, of Alset International Limited for a purchase price of 59,979,582 newly issued shares of the company's common stock. Following the closing of this transaction, AEI will own 55.52% of the company's outstanding shares of common stock and will be the majority shareholder of the company. On January 18, 2022, the company entered into a stock purchase agreement with AEI, pursuant to which AEI sold to the company 100% of the shares of common stock of its wholly owned subsidiary True Partner International Limited, and all of TP's 62,122,908 ordinary shares of True Partner Capital Holding Limited, for a purchase price of 11,397,080 newly issued shares of the company's common stock. The closings of these transactions are subject to approval of the NYSE and the company's stockholders. Transaction details will be filed in an 8-K with the U.S. Securities and Exchange Commission.

12:03 EST Snap restricts friend suggestions for teenagers - Snap said in a blog post yesterday that it is developing new measures to keep its community safe on Snapchat, including expanding its work to make the platform safer for minors. "As a platform built for close friends, we designed Snapchat to make it difficult for strangers to find and connect with minors," the company said. "For example, Snapchatters cannot see each other's friend lists, we don't allow browsable public profiles for anyone under 18 and, by default, you cannot receive a message from someone who isn't already your friend. While we know that drug dealers seek to connect with potential customers on platforms outside of Snapchat, we want to do everything we can to keep minors from being discovered on Snapchat by people who may be engaging in illegal or harmful behavior. We recently added a new safeguard to Quick Add, our friend suggestion feature, to further protect 13 to 17 year olds. In order to be discoverable in Quick Add by someone else, users under 18 will need to have a certain number of friends in common with that person -- further ensuring it is a friend they know in real life. In the coming months, we will be sharing more details about the new parental tools we are developing, with the goal of giving parents more insight into who their teens are talking to on Snapchat, while still respecting their privacy." Reference Link

12:00 EST Solo Brands falls -11.9% - Solo Brands is down -11.9%, or -$1.62 to $11.99.

12:00 EST Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 11.4% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 11.4%, or $6.62 to $64.84.

12:00 EST Harmony Gold rises 15.0% - Harmony Gold is up 15.0%, or 54c to $4.15.

11:54 EST BofA 'managing' human count, the firm's 'biggest cost,' says CEO Moynihan

11:47 EST Dingdong Cayman Limited (ADS) trading halted, volatility trading pause

11:42 EST Bank of America customers using Zelle more than writing checks, CEO says

11:36 EST Bank of America's investment banking pipeline 'healthy,' says CFO

11:33 EST BofA Wealth Management seeing consistent loan growth, says CFO

11:23 EST Bank of America sees 'robust' NII growth in 2022 vs. 2021

11:20 EST InterContinental unveils changes to loyalty program - InterContinental announced that its IHG Rewards loyalty program is making changes that will be introduced over the coming months, including a new tier and bonus point earning structure which will go live during March. Other enhancements include a new Gold Elite tier starting at 20 nights, a renaming of the "Spire Elite" tier to "Diamond Elite," and improving bonus point earn levels across all other Elite tiers. Keith Barr, CEO, IHG Hotels & Resorts, said: "If there's anything that has united the world in the last two years, it's the realization that no virtual platform can replicate the value of travel and making memories with those we love. Travel is its own biggest reward, and that's really at the heart of what we're doing with our loyalty program. Each time our members choose to stay at our hotels, we are increasing their opportunity to travel more, experience more, and reap benefits they won't get anywhere else. Our distinct portfolio of brands recognizes no two travelers are the same, helping guests and members make the right decision for all their travel needs."

11:16 EST IHG Hotels & Resorts uveils changes for loyalty program - IHG Rewards is sharing the first of many changes that will be introduced in the coming months. The new tier and bonus point earning structure - which will go live during March - is designed to help members earn more points faster and have more ways to use them than ever before. These changes, the first in a series of enhancements, include: Introducing a new Gold Elite tier starting at 20 nights, with an industry-leading 40% bonus point structure; Renaming of the 'Spire Elite' tier to 'Diamond Elite' to simplify member recognition and understanding of our highest tier, which will retain our best-in-class 100% bonus point structure ; Improving bonus point earn levels across all other Elite tiers.

11:12 EST LiveOne reports over 1.35M paid subscribers at end of 2021 - LiveOne announced certain preliminary operating metrics for calendar year 2021 and raised fiscal year 2022 financial guidance. LiveOne Ended Calendar Year 2021 with the following: 1.35 Million + paid subscribers, up 34.5% year-over-calendar year. 699,000 + total new LiveOne members. Added over 100 new blue chip sponsors. Livestreamed over 2,900 artists, 188 million livestream views, 155 events, and 58.9% engagement growth across its social and digital platforms. 115 pay-per-view events broadcasted on LiveOne's platform. LiveOne's wholly owned subsidiary PodcastOne had record metrics of over 2.48 billion podcast downloads. PodcastOne's popular LadyGang podcast surpassed 500 episodes. 33 new podcast shows joined the PodcastOne network consisting of 18 new shows and 15 existing shows that migrated to the PodcastOne platform. Launched over 100 new LiveOne radio stations. Completed a User Interface refresh of all "New" and "Top" stations within the Tesla in-car paid Slacker Radio streaming experience. Signed award-winning music curator and DJ, Kid O, to a multi-year contract to curate and host three new LiveOne mood-based, lifestyle stations. Used proprietary LiveOne mobile studio technology for an on-site, multi-day live audio broadcast from its Spring Awakening Music Festival. Launched the LiveOne Top 50 Songs of 2021 station, hosted and curated for the first-time-ever by five leading LiveOne radio format captains. Signed legendary Rock music host and evangelist Matt Pinfield to a multi-year contract as the new host of the "LiveOne Weekly Rock Countdown". LiveOne is implementing further cost and expense reductions from both operations and corporate overhead which is anticipated to increase the previously implemented $5.6M of annual cost savings to an estimated total of over $14M annually. LiveOne's 24-hour linear OTT streaming channel reaches over 294 million people on Amazon Fire, Roku, Apple TV, SLING, Xumo, and ReachTV, Consumable TV streaming original content, artist interviews, concerts, festivals, ancillary event-related content, and short-form video content from around the world. Announced in December 2020, LiveOne's board of directors authorized the repurchase of up to two million shares of LiveOne's outstanding common stock from time to time, subject to compliance with applicable laws and regulations. LiveOne reiterates its intent to repurchase up to 2 million shares of its common stock. As of December 31, 2021, LiveOne had approximately $14M in cash. LiveOne expects to report positive adjusted EBITDA in Q1 fiscal 2023 ending June 30, 2022.

11:11 EST Bank of America saw 1M new credit card accounts in Q4, says Moynihan

11:06 EST Dow Inc. enters multi-year offtake agreement with New Hope Energy - New Hope Energy announced that it has signed a multi-year offtake agreement with Dow to provide pyrolysis oil feedstock derived from recycled plastics collected in North America. The Lummus New Hope Plastics Pyrolysis Technology converts end of life plastic, diverting the waste away from landfills or the environment, into feedstock, which Dow will use to produce circular plastics. The technology is part of a partnership formed in 2020 between New Hope and Lummus Technology, combining Lummus' ability to license, scale-up and further develop process technology and New Hope's operational experience and waste conversion technology. New Hope Energy will produce the feedstock for Dow at its Trinity Oaks facility in Tyler, Texas. In addition, New Hope is in the process of expanding the existing Trinity Oaks production facility, utilizing technology jointly developed with Lummus. Final commissioning for the plant expansion is planned for late 2022.

11:04 EST Nuvei approved to process payments for online sportsbook operators in New York - Nuvei Corporation announces it has been granted approval by the New York State Gaming Commission to process payments with recently licensed digital sports betting platforms launching in the state. The commission approved five operators this month - Caesars Sportsbook, BetMGM, DraftKings, FanDuel and Rush Street Interactive - to accept mobile and online sports wagers. Nine operators are expected to be fully operational once regulatory approvals are finalised.

10:54 EST Kintara now sees top line data from Kintara arm of GCAR study near end of 2023 - In a regulatory filing last night, Kintara Therapeutics disclosed that in connection with the ongoing Global Coalition for Adaptive Research, or "GCAR," international registrational clinical study for glioblastoma multiforme, or "GBM," in which Kintara Therapeutics is participating in all three patient subtypes, GCAR has announced that the study has screened over 1,000 patients and that enrollment rates for the study are 3 to 4 times greater than traditional GBM studies according to GCAR, with active sites averaging 0.75 to 1 patient per site per month. "Based on continued dialogue with GCAR in connection with the study, the company has determined that it will not disclose graduation from stage 1 - safety and efficacy: 100-150 patients - to stage 2 - confirmatory: 50 additional patients. As a result of the accelerated enrollment rate, the company expects to announce top line data from the Kintara arm of the study around the end of calendar year 2023."

10:37 EST Sorrento completes enrollment in U.S. Phase 2 trial of COVI-DROPS - Sorrento Therapeutics announced that the U.S. Phase 2 study with intranasal COVI-DROPS treatment in COVID-19 outpatients has completed enrollment. This preliminary efficacy study enrolled 72 adult outpatients who received a single administration of 10 mg, 20 mg or 40 mg COVI-DROPS or placebo, randomized 1:1:1:1. The primary endpoint was viral load reduction from baseline. Key secondary endpoints included the proportion of subjects with medically-attended visits or hospitalizations and the change from baseline in the WHO Clinical Progression Scale score. There were no significant safety events reported during this study. Additionally, Sorrento announced that the UK Phase 2 study of intranasal COVI-DROPS treatment in COVID-19 outpatients who are asymptomatic or have mild symptoms has reached the interim analysis threshold of 50% enrollment. In this study, outpatient adults received a single instillation of 10 mg or 20 mg COVI-DROPS or placebo with a randomization of 2:2:1. The primary efficacy endpoint in the UK study is viral load reduction from baseline and key secondary endpoints also are similar to the US study. "Unlike the US study, this study uses a decentralized design where patients are assessed and treated in their homes. COVI-DROPS has also been well tolerated in this study. We anticipate reporting on the results from both the US trial and the interim analysis of the UK trial in the coming months. The results of these Phase 2 trials will be combined with the results from the planned Phase 2 trials in Mexico which enrolls children as well as adults. In contrast to some of the current EUA approved high dose neutralizing antibodies given by IV infusion or subcutaneous injection, COVI-DROPS is administered as a simple intranasal instillation into each nostril to recently infected subjects. The neutralizing antibody in COVI-DROPS is the same antibody as in COVI-AMG, which is a high potency/low dose IV push injection. This nAb was active in vitro and in animal models of COVID-19 infection against the SARS-CoV-2 variants of concern including the highly transmissible and virulent India/Delta variant, as well as the UK/Alpha variant and the original SARS-CoV-2 virus," the company stated.

10:35 EST Axsome Therapeutics says provided response to FDA on NDA deficiencies - In a regulatory filing last night, Axsome Therapeutics reported that the company has provided a response to the U.S. Food and Drug Administration addressing the two, previously disclosed, deficiencies related to analytical methods in the Chemistry, Manufacturing, and Controls section of the company's New Drug Application, or "NDA," for AXS-05 for the treatment of major depressive disorder. "At this time, Axsome has not been made aware of any other deficiencies related to the NDA by the FDA," the company stated in its filing.

10:34 EST State Street sees FY22 fee revenue up 3%-4%, NII up 10%-12% - Sees FY22 effective tax rate 17%-19%. Expenses expected to be up 1.5%-2% for FY22.

10:03 EST DraftKings, Tulalip Tribes of Washington to operate sports betting - DraftKings and the Tulalip Tribes of Washington announced an exclusive market access partnership that will bring the DraftKings retail sportsbook experience to the state of Washington. Plans are underway to open DraftKings retail sportsbook locations at Tulalip Resort Casino and Quil Ceda Creek Casino, both located just 30-minutes north of Seattle in Tulalip, WA. Initial design plans for the DraftKings Sportsbook at Tulalip Resort Casino, pending licensure and regulatory approvals, will feature a 5,000 square-foot space with a 50-foot video wall and more than two dozen kiosks and eight ticket windows. The design of the DraftKings Sportsbook at Quil Ceda Creek Casino is still early in the planning phase but is expected to feature state of the art technology and share the same world-class betting experience found across all DraftKings branded retail sportsbooks.

10:01 EST BAE Systems awarded $60M contract from Army Contracting Command - BAE Systems (BAESY) has been awarded a $60M contract from the Army Contracting Command - Rock Island under the Cornerstone Other Transaction Authority to develop certain types of next-generation, radiation hardened by design microelectronics leveraging Intel's (INTC) commercial foundry, Intel Foundry Services. The main goal of the program is to expand onshore access to state-of-the-art microelectronics technology for the United States government and aerospace community.

10:00 EST Studio City falls -6.1% - Studio City is down -6.1%, or -37c to $5.70.

10:00 EST Dingdong falls -15.5% - Dingdong is down -15.5%, or -$1.24 to $6.76.

10:00 EST Casper Sleep rises 11.6% - Casper Sleep is up 11.6%, or 60c to $5.80.

09:58 EST Bank First Corporation to acquire Denmark Bancshares for consideration of $119M - Bank First Corporation announced the signing of an Agreement and Plan of Merger with Denmark Bancshares, parent company of Denmark State Bank, a Wisconsin state-chartered bank, under which Bank First has agreed to acquire 100% of the common stock of Denmark in a combined stock-and-cash transaction. Under the terms of the Agreement and Plan of Merger, each Denmark shareholder will have the option to receive either $38.10 in cash per share or 0.5276 of a share of Bank First's common stock in exchange for each share of Denmark common stock, subject to customary proration and allocation procedures, such that no less than 80% of Denmark shares will receive stock consideration and no greater than 20% will receive cash consideration. The aggregate consideration is valued at approximately $119 million. As of December 31, 2021, Denmark had approximately $687.6 million in consolidated assets, $479.4 million in gross loans, $614.5 million in deposits and $68.0 million in consolidated stockholders' equity. Based on the financial results as of December 31, 2021, the combined company will have total assets of approximately $3.6 billion, loans of approximately $2.7 billion and deposits of approximately $3.2 billion. The Agreement and Plan of Merger has been approved by the Boards of Directors of Bank First and Denmark. The closing of the transaction, which is targeted to take place early third quarter 2022, is subject to customary closing conditions, including regulatory approval and approval by the shareholders of Denmark and Bank First. The two institutions offer a diverse set of competencies that when combined are expected to result in a stronger organization. Denmark has established itself as a leading provider of financial products and services in Northeast Wisconsin, resulting in a strong deposit base. This complements Bank First's already strong presence in Manitowoc County and enhances its growing footprint in Brown County. Bank First recently announced the purchase of a seven acre parcel of property to build a new flagship office along Shawano Avenue and South Taylor Street next to the Meijer store in Green Bay, solidifying its commitment to Green Bay and the surrounding communities. Denmark's customers will benefit from Bank First's 49.8% ownership of UFS, LLC, a bank technology outfitter which provides digital, core, cybersecurity, managed IT, and cloud services to banks in the Midwest. Bank First's relationship with UFS creates opportunities to access the latest advancements in banking technology at a faster rate than its peers.

09:48 EST Minerva Surgical Inc trading halted, volatility trading pause

09:47 EST Maui Land & Pineapple falls -6.3% - Maui Land & Pineapple is down -6.3%, or -63c to $9.33.

09:47 EST Dingdong falls -14.2% - Dingdong is down -14.2%, or -$1.14 to $6.86.

09:47 EST Mechel rises 8.7% - Mechel is up 8.7%, or 24c to $3.07.

09:44 EST Procter & Gamble says China business well-positioned for growth - Says almost all products consumed in China are made in China. Says "fully committed" to productivity gains as means to expand margins. Says majority of price increases announced have not yet hit the market. Says better positioned to deal with inflationary environment "than ever before." Says currently has very healthy portfolio and it assumes 100% organic growth, so no need for large M&A. Says commodity cost increases y/y "continue to be material."

09:40 EST Plug Power sees FY25 revenue $3B, 20% EBITDA margin

09:40 EST Intergrated Media Technology Ltd trading resumes

09:38 EST Vaxxinity Inc trading halted, volatility trading pause

09:33 EST TKLF Stock trading halted, volatility trading pause

09:29 EST UnitedHealth says growing market share once again - Says investing in multi-year growth platforms. Says pleased in way Optum Care has developed. Says set up retention for key staff. Says comfortable with multi-channel distribution approach. Says home delivery and specialty businesses are benefitting from investment in digital. Comments taken from Q4 earnings conference call.

09:26 EST Gorman doesn't expect to be CEO at Morgan Stanley in 5 years, he says

09:23 EST U.S. Bancorp sees FY22 NII up mid single digits on taxable equivalent basis

09:22 EST DigitalBridge buys four existing Texas data centers from CyrusOne for $670M - DigitalBridge Group (DBRG) announced that its portfolio company DataBank, a provider of enterprise-class colocation, interconnection and managed cloud services, has agreed to acquire four existing data centers in the Houston, Texas metro area from CyrusOne (CONE), a global data center REIT, for $670M. The transaction positions DataBank as the largest independent data center provider in Houston, the nation's fourth-largest metro area. The new facilities will collectively add more than 300,000 square feet of raised-floor data center capacity and 42.5 MW of installed critical IT load, as well as a roster of blue-chip customers from the area's fast-growing healthcare, financial, energy, media and software sectors. Additionally, one of the facilities being acquired - the Houston West Campus - is the region's primary interconnection point, with over 30 fiber networks, 3,500 cross connects and public cloud on-ramps from AWS and Google. Located along a major fiber corridor in Houston, the Houston West Campus is strategically positioned with access to significant and redundant utility power feeds and access to the fastest and most reliable telecommunications networks. The transaction is being funded by an investor group led by DigitalBridge, DataBank's controlling shareholder. In addition to leading a consortium of world-class institutional investors to support the acquisition, DigitalBridge is investing $80M from its balance sheet to maintain its 20% ownership position in DataBank. Following the close of the transaction, DataBank's total portfolio will feature more than 65 facilities and 2.0 million square feet of raised-floor data center capacity. The third quarter 2021 annualized run-rate cash NOI represented by these acquired properties, including certain future contracted lease payments, aggregate $34.8M, and the acquisition includes 100% ownership of the underlying real estate. The transaction is expected to close late in the first quarter of 2022, subject to customary conditions and regulatory approvals.

09:21 EST Matterport announces sales increase for Allseated Hospitality clients - Matterport is "transforming the event planning industry with technology platform partner, Allseated," the company said. Using Matterport's digital twins to create its virtual venues, Allseated gives venues a way to showcase their event spaces and book events without the need for onsite meetings. To date, the partnership has driven: 30% increase in sales for Allseated hospitality clients investing in digital twin-based virtual venue tours and space planning tools. 60% greater operational efficiency for venues and event professionals who save 2.5 hours in time spent diagramming and managing day-of set up errors. More accurate space dimensions and visual details. "As the world continues to adapt to a variety of ways to attend events, virtual planning and attendance is very effective and highly efficient," said Bill Linehan, Global Strategy Lead for Travel and Hospitality at Matterport. "Matterport is well on its way to digitizing the built world so companies can utilize digital twins to be more efficient and productive. We are pleased to support Allseated as they digitally transform the events industry and take it virtual."

09:19 EST Momentive urges shareholders to vote for all proposals on Zendesk transaction - Momentive Global (MNTV) mailed a letter to stockholders in connection with the Special Meeting of Stockholders that has been called to approve proposals relating to the Company's previously announced transaction with Zendesk (ZEN). The Momentive Board of Directors unanimously recommends that Momentive stockholders vote on the WHITE proxy card "FOR" all proposals relating to the proposed transaction with Zendesk ahead of the Special Meeting, which has been scheduled for February 25, 2022. The letter read in part, "You will be asked to make an important decision regarding the future of our company at Momentive's Special Meeting of Stockholders, which is scheduled to be held on February 25th. As a stockholder of Momentive, you will have the opportunity to approve the Company's proposed combination with Zendesk, which is designed to deliver enhanced value for our stockholders and customers by creating a differentiated platform that gives businesses what they need - deeper customer intelligence. With a broader set of solutions and a demonstrably larger customer base to cross sell against, Zendesk and Momentive will be uniquely positioned to serve a global market and generate significant growth. Put simply, this transaction will enable Momentive stockholders to participate in the upside potential of a larger scale, faster growing company with a strong profitability profile...The Momentive Board of Directors is confident that combining with Zendesk will maximize value for the Company and its stockholders. The Momentive Board undertook a comprehensive strategic review process before unanimously determining that the Zendesk transaction is the best path forward for the Company with compelling financial benefits to Momentive stockholders."

09:15 EST Charles River, Valo Health form multiyear strategic partnership - Charles River and Valo Health announced the formation of a multiyear strategic partnership. This agreement will combine Valo's Opal Computational Platform with Charles River's drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform. Recognizing the challenges of preclinical drug discovery, from high costs, time, and attrition rates, Valo and Charles River have joined forces to create enhanced drug discovery solutions that aim to transform the entire preclinical drug discovery process. Valo and Charles River intend to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences. The partnership's combined offerings will utilize Valo's Opal Platform for small molecule development, which leverages a "closed-loop" in silico-experimental platform that rapidly iterates using program data to identify novel compounds, and leverages Charles River's capabilities in all aspects of discovery optimization, including medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission. The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River.

09:13 EST Arcimoto, Adventure Center to begin FUV rentals in Fort Lauderdale, Florida - Arcimoto and Adventure Center announced that they will begin renting Arcimoto Fun Utility Vehicles, FUV, in Fort Lauderdale beginning in February 2022. "Adventure Center has long been leading the charge for three-wheel vehicle rentals in South Florida, and we are thrilled to now offer their customers a pure electric option." said Mark Frohnmayer, Arcimoto Founder and CEO. "This partnership continues to build upon Arcimoto's destination rental strategy, driving revenue per vehicle built, as well as brand awareness as happy customers cruise FUVs up A1A, and beyond. There is simply no better advertising."

09:13 EST Issuer Direct appoints Tim Pitoniak as CFO - Issuer Direct announced that effective January 24, Tim Pitoniak will join the company as its new CFO, and Steve Knerr will take on the new role of VP of finance and controller. Pitoniak will provide leadership and oversight of the company's financial operations, reporting, planning, and select other functions. Pitoniak brings more than 20 years of financial experience primarily for public companies, with an extensive background in financial planning, operations, management and strategy.

09:12 EST UpHealth names Edna Boone Johnson Chief Communications and Marketing Officer - UpHealth has appointed Edna Boone Johnson as Chief Communications and Corporate Marketing Officer, effective immediately. Johnson's previous employers include Michelin North America, Burger King Corporation and the CNN News Group. Before joining UpHealth, Johnson served at Michelin for more than a decade.

09:11 EST Usio announces city in California chooses company's prepaid card technology - Usio announced that the City of Oakland Department of Transportation, California, has chosen the Company's proprietary prepaid card technology as the payment solution for its groundbreaking Universal Basic Mobility Pilot. Louis Hoch, President and Chief Executive Officer of Usio, said, "As the acknowledged leader in electronic payments solutions for guaranteed income programs, we are pleased to have developed innovative technology that will help the Oakland DOT make access to their transportation network more affordable to those in need. Like the numerous other guaranteed income programs we support around the country for governmental entities both large and small, we developed a customized payment solution for Oakland DOT that provides a contemporary payment technology that is responsive to both their needs as well as those of their constituents. I want to thank the Oakland DOT for their confidence in Usio, and we look forward to supporting this very worthy program." Under this pilot program, citizens living or working in East Oakland can apply to receive up to $300 that can be used only for transit and shared mobility on a prepaid debit card. Up to 500 participants have been randomly selected from qualified applicants.

09:10 EST Morgan Stanley 'cognizant' of pressure on expenses, will 'pay for performance'

09:09 EST CyrusOne to divest four Houston data center assets for $670M - CyrusOne announced it has entered into a definitive agreement with DataBank for the sale of its four Houston data center assets. Under the terms of the agreement, DataBank will acquire the Houston West I, II and III and Houston Galleria data centers from CyrusOne. Additionally, CyrusOne will lease back from DataBank the Houston West III shell to support a lease signed with a hyperscale customer in Q4. Total consideration for the transaction will be approximately $670M, subject to a net working capital adjustment, with proceeds from the sale used to fund future development projects. The Q3 annualized run-rate cash NOI represented by these properties, including the future first year lease payments that will be made by CyrusOne, aggregate $34.8M, implying a transaction cap rate of 5.19%. The divestiture is expected to close by the end of the first quarter of 2022, subject to customary closing conditions.

09:08 EST Hims & Hers names Yemi Okupe as CFO - Hims & Hers Health announced a number of leadership appointments that firmly position the company for success in pursuit of its mission to transform the legacy healthcare and wellness industry. The company has named Yemi Okupe , a PayPal (PYPL), eBay (EBAY), Google (GOOG), Braintree, and Uber (UBER) veteran with a decade of experience scaling high-growth, industry-disrupting companies - as Chief Financial Officer. Additionally, Hims & Hers Chief Medical Officer Dr. Patrick Carroll is being elevated to the company's Board of Directors. We're delighted to welcome Yemi to the Hims & Hers family," said Hims & Hers CEO Andrew Dudum. "Yemi's superpower is taking high-growth companies with the potential to transform entire industries and helping them to seize that opportunity, scale rapidly, and build a business for the long-term. We could not have found a better person to help lead us through this next phase of growth as we continue our efforts to remake the healthcare and wellness industry."

09:07 EST Chase to be exclusive issuer of Instacart credit card - Chase (JPM) and Instacart announced an expansion of their existing partnership to make Chase the exclusive issuer of Instacart's first credit card. As a part of this partnership, Mastercard (MA) will become the exclusive payments network for the new offering. The new Instacart Mastercard credit card will be the first Chase co-branded card offering in the on-demand grocery delivery space. The card will allow consumers to earn accelerated points on purchases across the Instacart marketplace, which includes more than 700 national, regional and local grocers and retailers. The card is expected to launch in 2022 and will also offer a number of other benefits, perks and savings.

09:06 EST Philips to support AHA's efforts to raise awareness of CIED infections - Royal Philips is supporting the American Heart Association's, AHA, effort to generate awareness among cross-disciplinary specialties and improve survival rates from cardiovascular implantable electronic device, CIED, infections. With the support of Philips, the American Heart Association's national CIED infection initiative will work with medical professionals across a variety of specialties to prevent and properly treat infections resulting from cardiovascular implantable electronic devices such as pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices. "By supporting the American Heart Association, we have a significant opportunity to improve care for a large group of cardiovascular patients," said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. "At Philips, we want to support medical professionals and their efforts to follow guideline-directed care and decrease the complications and negative outcomes that too often follow CIED infections."

09:05 EST First Community reports Q4 EPS 52c, consensus 49c - Reports Q4 loan loss provision ($59K) vs. $276K a year ago. Reports Q4 net charge-offs ($213K) vs. $0 a year ago. Tangible book value per share was $16.62 at quarter end from $16.37 at previous quarter end.

09:03 EST Seanergy Marine announces additional $5M buyback of convertible notes - Seanergy Maritime Holdings announced an aggregate of $5 million in buyback and partial elimination of the outstanding convertible note, utilizing 50% of its second share repurchase plan. As previously announced and following the full completion of the first share repurchase plan, the Board of Directors authorized the additional Plan, under which the Company might repurchase up to an additional $10 million of its common shares, convertible notes or warrants. The Note carries a 5.5% coupon, has a $1.20 per share conversion price and is held by Jelco Delta Holding Corp. Based on the conversion price, the buyback is preventing potential dilution of 4.17 million shares. Seanergy will realise annual interest savings of $275,000 as a result of the deleveraging effect of the prepayment. Moreover, the Company's cash sweep obligations for 2022 under its outstanding loan and Note with Jelco have been waived. The Company expects to record a non-cash accounting loss of approximately $1.5 million in the first quarter of 2022, associated with the accounting treatment of the Note. Nonetheless, the prepayment will have a positive impact on the income statement for 2022-24 through the elimination of non-cash charges of an average of $0.5 million per year.

09:02 EST AvePoint launches Confide virtual data room - AvePoint launched Confide, a virtual data room to help businesses manage sensitive data needs, and collaborate with greater confidence. Confide is the only virtual data room fully integrated with Microsoft 365, and hosted on the end-user cloud tenant, providing optimal security and initiation efficiency. Confide enables businesses to seamlessly work with both internal and external actors, without the concern of data breaches, accidental exposure, and costly mistakes, especially when engaging in highly confidential projects like mergers and acquisitions, financial audits, intellectual property, and executive collaboration.

09:01 EST Stem Holdings granted adult-use license for existing Sacramento dispensary - Stem Holdings announced being granted an adult-use license for its existing Foothills Health & Wellness 4,600 square foot retail storefront in Sacramento, California. In 2021, this location generated approximately $5.5 million in medicinal retail cannabis sales. Management believes it possible to double annualized sales at this location under adult-use.

08:54 EST Cross Country Healthcare CEO to transition to chairman, John Martins to succeed - Cross Country Healthcare announced that Kevin Clark, co-founder and CEO of the company will transition from his current role as president and CEO effective March 31 to chairman of the company's board of directors, where he will continue to lead Cross Country Healthcare's strategic direction. In connection with this transition, John Martins, group president, delivery, will be promoted to president and CEO of the company and appointed to the company's board of directors. Thomas Dircks, who has served as the company's chairman since 2013, will continue to serve as an independent director of the company's board of directors. Larry Cash will continue to serve as the company's lead director.

08:48 EST Quantum Computing introduces Quantum Consulting, four-phase framework - Quantum Computing announced its consulting practice, QCI Qonsulting, and Path2Quantum, a four-phase framework that organizations can use to explore, measure, and strategically plan their quantum computing adoption. The company also announced its first Qonsulting customer, employee staffing company Quad M Solutions. QCI will deliver quantum-ready solutions to Quad M for optimization of its health insurance underwriting services. QCI Qonsulting engagements leverage proven expertise in vendor-neutral quantum software and algorithms, as well as the company's ready-to-run quantum software, Qatalyst. QCI believes that Qonsulting will empower organizations to chart a comprehensive strategic path to quantum, while dramatically de-risking time and investment in early quantum exploration. QCI's Qonsulting and Qatalyst offer a simpler, more efficient choice by providing organizations with a straightforward path to explore a wide array of quantum options across diverse QPUs with no need for expensive quantum development. They benefit from a comprehensive and accelerated quantum exploration with a much lower associated investment and risk. Qonsulting also features Qatalyst ready-to-run quantum software, providing business users with straightforward access to quantum computing. Business subject matter experts learn to easily model, submit, and solve their problems on quantum-ready and quantum systems, with no quantum expertise required. Primary to Qonsulting is the commitment to chart and execute a practical and successful pathway to quantum. QCI's P2Q framework defines four flexible phases in the journey to initial and ongoing quantum value. Each phase builds on the exploration and lessons learned from the previous phase. This results in organizations defining a comprehensive and strategic plan for quantum computing adoption. Companies may start at different points based on their needs and readiness. The framework is outlined briefly below: Phase I: Identify expectations, evaluate quantum-possible use cases/problems/applications and prioritize quantum-possible opportunities. Phase II: Explore quantum hardware and software options, define best infrastructure to test and measure for specific quantum-possible problems. Phase III: Test quantum problems and infrastructures across diverse configurations, from quantum-ready classical to hybrid to pure quantum, tune problems, measure potential. Identify the best possible strategic phases to move forward with quantum, including target infrastructures, timing for each phase as QPUs advance, and expected results at each stage. Phase IV: Begin initial processing based on the Phase III plan. Test, refine and continue to advance, as clients identify the next quantum-possible opportunities in the successive Phase I.

08:47 EST Streamline Health announces contract with medical center in North Carolina - Streamline Health Solutions announced it has signed a contract with an Epic EHR-based regional medical center located in Eastern North Carolina. The nearly 700-bed medical center will use eValuator's automated pre- and post-bill coding analysis technology to help improve revenue integrity and financial performance from their inpatient and outpatient services. "Providers understand the need to proactively address coding accuracy on all claims prior to billing, and we're excited to have another North Carolina-based healthcare organization select eValuator to help them achieve this goal," stated Tee Green, President and Chief Executive Officer, Streamline Health. "Accurate coding helps optimize financial performance, ensuring that providers have the financial resources they need at this critical time."

08:45 EST Morgan Stanley 'fully expects' to achieve goals, says CEO Gorman

08:44 EST Full House Resorts revises budget for Chamonix Casino Hotel to $250M - The Company also announced that it has increased the anticipated investment for its luxury Chamonix Casino Hotel, currently under construction in Cripple Creek, Colorado. The revised Chamonix budget is $250 million, reflecting completion of sub-contracting of much of its hard-dollar construction budget. The increased construction costs reflect supply chain issues, inflation, and a difficult construction environment. Management believes that there will not be further budget increases. The Company has sufficient cash and resources to complete the project at the higher budget number and is, accordingly, transferring cash to its restricted construction cash account to fund the increased construction costs, in accordance with its debt covenants.

08:42 EST Morgan Stanley sees $500M of incremental NII in wealth management this year

08:40 EST Tivic Health starts 2nd study of bioelectronic platform as opioid alternative - Tivic Health Systems announced initiation of its second clinical study investigating the extension of the company's bioelectronic platform, "offering a potentially new alternative to opioids for post-operative care following sinus surgeries,' said the statement. This 60-person double-blind, randomized controlled trial will be conducted with an international hospital leading in medical and scientific training, biomedical research, and patient care. Tivic Health currently offers an FDA-cleared bioelectronic treatment for sinus pain and nasal congestion - a condition that impacts over 200-million U.S. adults. The upcoming trial will investigate the extensibility of Tivic Health's platform as a specialized treatment for pain following functional endoscopic sinus surgery, an intervention involving removal or modification of bone and tissue in the sinus airway passages. Tivic Health previously completed an open-label pilot study with the U.S. Institute for Advanced Sinus Care and Research comparing different programming modes for the device. Clinical measures for the newly initiated study will include postoperative pain and use of opiate medication during the study period.

08:39 EST IMAC announces repayment of three loans - IMAC Holdings has announced the repayment of three loans representing more than 95% of its debt in accordance with scheduled debt service over the past 10 months. From March 28, 2021, to January 18, 2022, IMAC Holdings paid significant loan balances to retire over $4.35 million in loans payable. The Company has approximately $200,000 of debt remaining on the balance sheet related to equipment and construction loans.

08:37 EST Verizon Business announces new Business Unlimited Data Device plans - Verizon Business announced its new Business Unlimited Data Device plans. The new plans power businesses with the faster, reliable and secure network for work in the office or on the go. These plans are in addition to Verizon's new 5G Business Internet solutions. The new data device plans come as the Verizon 5G Ultra Wideband network becomes available to 100 million more people in 1,700-plus cities around the nation this month, offering access to speeds up to 10x faster than 4G LTE3. 5G Ultra Wideband enables transformative speed and reliability to power businesses of any size. Starting tomorrow, Verizon Business is offering businesses two customized offerings to take advantage of the 5G Ultra Wideband Network as well as an increased premium data allotment and enhanced video streaming capabilities. Business Unlimited Plus Data Device: For $45 a month, businesses can unlock 60 GB of combined 5G Ultra Wideband, 5G Nationwide, and 4G LTE premium network access. To enable remote work and collaboration these plans include mobile hotspot usage as a part of all data plans and video streams that can reach 4K with 5G Ultra Wideband. Business Unlimited Pro Data Device: For $75 a month businesses can unlock all the features of Business Unlimited Plus Data Device with 100GB of premium network access.

08:37 EST Ballard Power receives additional fuel cell order from Canadian Pacific - Ballard Power (BLDP) received an order for eight additional 200 kW fuel cell modules to support the expansion of Canadian Pacific's (CP) Hydrogen Locomotive Program from one to three locomotives, with expected delivery in 2022. Inclusive of Ballard's announcement in March 2021, the company will provide a total of 14 fuel cell modules, each module with a rated power output of 200 kW, to support this program. CP intends to refine the process of converting diesel-electric powertrains to hydrogen-electric powertrains over a series of three categories of locomotives.

08:36 EST Taoping enters into agreement to acquire Zhenjiang Taoping IoT Technology - Taoping announced that it has entered into a share purchase agreement to acquire 95.56% equity interest in Zhenjiang Taoping IoT Technology, aiming to accelerate the Company's smart charging pile and digital media businesses in East China. "After the closing of the acquisition, Zhenjiang Taoping is expected to become an important part of Taoping Digital Culture East China Operation Center," the company said. "With a high level of economic development and urbanization, the target market of our East China Operation Center has great potential in the construction of new smart communities," said Jianghuai Lin, Chairman and CEO of TAOP. "The acquisition of Zhenjiang Taoping will help the Company to quickly deploy smart charging pile and digital media businesses in East China market. We believe this transaction would bring value for our shareholders and optimize TAOP's business structure." About the Transaction: Pursuant to the share purchase agreement, as consideration TAOP has agreed to issue to the shareholders of Zhenjiang Taoping a total of 201,552 restricted ordinary shares of TAOP, calculated as $391,011 being divided by the average closing price of TAOP ordinary shares over the 20 trading days prior to the execution of the share purchase agreement, which was $1.94 per share. These shares are offered pursuant to an exemption from the registration requirements of Section 5 of the Securities Act of 1933, as amended contained in Section 4(a)(2) thereof and/or Regulation S promulgated thereunder. The parties intend to close the transaction no later than January 31, 2022.

08:35 EST NanoVibronix files three patents apps with USPTO related to its SAW technology - NanoVibronix announced it has filed three U.S. patent applications with the U.S. Patent & Trademark Office related to its SAW technology and indwelling medical devices to protect targeted new product launches and improvements to existing medical devices. Brian Murphy, Chief Executive Officer of NanoVibronix commented, "Our patented SAW ultrasound technology has proven effective in treating pain, as well as inhibiting infections associated with urological conditions. Beyond just urology and pain management, our expanding patent portfolio is driven by our commitment to continue exploring different applications and developing new products that leverage our unique technology. "For example," noted Murphy, "one of our new applications relates to cosmetic applications of our technology to reduce signs of aging and improve skin texture. In line with the growing use of ultrasound in cosmetic dermatology, our SAW-generating devices and facial patches address a host of cosmetic and topical concerns. Importantly, this represents a new and sizeable market opportunity for us." "In addition, we believe that we have made material improvements to the assembly and operational configuration of indwelling medical devices incorporating our SAW-generating technology," added Murphy. "The new patent applications provide for new stand-alone devices, such as a novel catheter, intravenous needle assembly and percutaneous endoscopic gastrostomy tube. More generally, described in the new applications is an ultrasound system that effectively transforms any such indwelling medical device into a therapeutic device. The generation of SAW along the surface of our indwelling medical devices produces nano-vibrations sufficient to inhibit the colonization of bacteria and, as a result, the formation of bacterial biofilms that are commonly known to adhere to surfaces of conventional indwelling devices. Therefore, we believe that a significant improvement of our indwelling devices is the accompanying antimicrobial prophylactic effect for preventing infections associated with conventional indwelling medical devices. Given that infections stemming from indwelling devices account for up to twenty percent of annual healthcare-associated infections in hospitalized patients, coupled with the resulting prolonged hospitalization stays and increased costs per admission, our technology should provide readily recognized and broadly applicable advantages."

08:35 EST Morgan Stanley entered 2022 'ahead of plan,' says CEO James Gorman - Comments taken from Q4 earnings conference call.

08:35 EST Vicinity Motor secures C$14M order from Pioneer Auto Group - Vicinity Motor announced that it has secured a C$14M order from Pioneer Auto Group, a retail automotive dealer in British Columbia, for 100 VMC 1200 Class 3 electric trucks. The Pioneer Group has been appointed to act as VMC's exclusive dealer in the province of British Columbia - this follows a previous letter of intent.

08:34 EST Fortune 100 tech company goes live with Bridgeline - Bridgeline Digital announced that a Fortune Top 100 technology company has gone live with Bridgeline's site search software on their website.

08:33 EST Akari announces FDA has agreed to new manufacturing process for nomacopan - Akari Therapeutics announced that the U.S. Food and Drug Administration, FDA, has agreed, via a Type C meeting, to the clinical use of nomacopan derived from a next generation manufacturing process. Nomacopan is Akari's lead drug candidate currently in two Phase III programs. The FDA agreed that the new manufacturing process produces drug that is comparable to nomacopan from the prior manufacturing process. The new manufacturing process increases the final yield of nomacopan at least 5-fold, compared to the previous manufacturing process. "FDA's agreement for our use of the new and enhanced manufacturing process is a key milestone in the pathway to commercialization of nomacopan," said Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics. "The FDA's agreement is the culmination of several years' work, and I would like to thank Akari's Head of CMC, Mukesh Sehdev, and our long-term partners in the manufacture of nomacopan, Wacker Biotechnology GmbH and Solvias AG, for their strategic planning, commitment and the quality of their work."

08:32 EST Foothills Exploration provides January 2022 corporate update - Foothills Exploration is pleased to announce a corporate update and outlook for 2022. HHE Exploration Technologies has completed full integration of its hydrogen sensing drone platform and is preparing to test the Unmanned Aerial System over known areas of natural hydrogen emanations within 30 days. After field testing is completed, HHE will initiate multiple exploration programs in North and South America concentrating on natural hydrogen, which has the potential to drastically accelerate the global energy transition to net zero. The field of natural hydrogen exploration has recently emerged on the international stage as a potentially viable alternative hydrogen production method with costs projected to be significantly lower than steam methane reforming and electrolysis using renewable energy. Natural hydrogen is clean and carbon-free with production costs estimated to be about $0.75 per kilogram, which is about 1/8th the current cost of producing green hydrogen. Hydrogen is also gaining unprecedented economic and political momentum globally as an alternative net-zero energy vector and a complement to the 'electrify everything' movement. Bank of America forecasts that the hydrogen industry is at a tipping point and headed to $11 trillion, with hydrogen production projected to see a 5,000% increase by 2026. Global demand for clean and green energy continues to increase rapidly, coupled with the need to optimize production, and minimize greenhouse gas emissions. The Houser-Sears well recompletion was successful with the well's initial production coming in at around 33 barrels of oil per day and now settling in at approximately 16 BOPD. The Company plans to perform workover and stimulation operations on five (5) targeted wells during the remainder of Q1 on the Company's recently acquired properties in the Illinois basin. For more information on these properties, please refer to the Company's press release issued on December 31, 2021. The Company is currently evaluating several opportunities in the basin to acquire production or selective infield drilling prospects to grow its footprint. Based on discussions with the Bureau of Land Management, review of Federal lands and recommendation from a professional federal drilling unit service company processing application, the Company's current focus is to begin the Notice of Staking and Application Permit to Drill process for Beaver Creek East unit obligation well. A BLM unit application meeting is being scheduled. The licensed seismic identified and confirmed structural features for initial drilling pad location. Unitized formation is designated as the "Frontier Formation." Timing issues for initial drilling will depend on State and BLM well permitting, rig availability and pad location construction. The Company has made the Wind River Basin project a top priority for 2022. The Company is up-to-date with all of its required financial alternative report filings and is OTC Pink current. The Company's 2021 annual report is also on track to be filed with OTC Markets prior to the filing deadline. The Company has retained its historical auditors, RBSM, LLP, and continues to work through the auditing process with the aim of uplisting back onto the OTC.QB as soon as possible.

08:32 EST Esports Technologies sees 10-month revenue $70M - Esports Technologies reported financial guidance for the 10-month period from December 2021 to September 2022 in which it anticipates revenue of $70M. This projected revenue and related growth is derived primarily from the company's online sportsbook and casino brands. The brands were acquired by Esports Technologies on November 29, 2021, two months into the company's fiscal year. The subject 10-month period is from the closing of the brand acquisition until the end of the September 30 fiscal year. CEO Aaron Speach said, "As we begin a successful 2022, we remain committed to increasing our operational and financial performance. We expect to deliver consistent cash flow for the remainder of 2022 by growing esports revenue in regulated markets, as well as continued growth from our portfolio of online sportsbook and casino brands."

08:21 EST Morgan Stanley long-term efficiency ratio goal is under 70% - Other long-term goals include ROTCE of 20%+ and WM pre-tax margin of 30%+. A longer-term goal is to have client assets of $10T, the company said in slides that will be presented on its Q4 earnings conference call.

08:18 EST M Health Fairview receives first Hyperfine Portable MRI - Hyperfine announced that M Health Fairview is deploying a Swoop system in the emergency room, intensive care unit and post anesthesia environments at M Health Fairview University of Minnesota Medical Center. The hospital is the first in the state of Minnesota, and one of the first in the country, to offer this technology to its patients.

08:16 EST Quanta's Medolife Rx submits final clinical trial data for Escozine approval - Medolife Rx announced that the Company submitted the final clinical trial data to the Dominican Republic Ministry of Health for approval of the Company's product, Escozine, as a COVID-19 treatment. The product, which is registered as an alternative oncological medicine in the DR, has shown to be effective against variations of the SARS-CoV-2 virus. After the recent meeting between Medolife CEO Dr. Mikaelian and DR Vice-President Raquel Pena de Antuna that concluded with interest from the government to register the product as a treatment for COVID-19 in the country, the Company was required to present data to various governmental institutions prior to receiving a governmental order for Escozine, such as: Program for Essential Medicines and Logistical Support Center; National Health Insurance; High-Cost Medicines and Medical Assistance Program. The information was received well by these institutions, and the Company was directed to seek final approval for Escozine as a COVID-19 treatment from the DR MoH. The final medical and scientific data on Escozine has been submitted to the office of the DR Minister of Public Health Daniel Rivera, and the DR Vice-Minister of Public Health Eladio Perez Antonio. Since then, the Company also had a video conference with Mr. Rivera and members of the DR MoH, where Dr. Mikaelian and Medolife Chief Scientific Officer Dr. Khalid Matalka presented the data on Escozine. A video conference was suggested by MoH due to the high rate of Omicron cases registered in their administration. During the conference, Dr. Matalka demonstrated Escozine's mechanism of action as a calcium ion channel inhibitor, which prevents the SARS-CoV-2 virus from entering the host cell, meaning Escozine can be an effective therapy against variants of the virus. Upon the completion of the data review, the DR MoH will decide whether to approve Escozine as a COVID-19 treatment, or to simply include it in the treatment protocol against COVID-19 using its existing registration in the DR as a cancer treatment. End of January, the Company also plans to request a meeting with the United States Food & Drug Administration in order to explore the possibility of a change from PIND to IND status and approving Escozine for a 30-to-60 patient pilot study to show proof of concept within the US.

08:13 EST Honda, SES Holdings enter joint development agreement for Li-Metal batteries - SES Holdings announced that it entered into a joint development agreement with Honda (HMC) to develop Li-Metal batteries as part of Honda's next generation battery strategy. The partnership marks a milestone on SES' roadmap to achieve commercial production of hybrid Li-Metal batteries for electric vehicles. Honda joins General Motors (GM) and Hyundai Motor Company as the third major global car manufacturer to enter into an "A-sample" joint development agreement with SES. Honda previously agreed to invest in the combined company as part of the common stock private investment in public equity, or PIPE, financing in connection with SES' pending business combination with Ivanhoe Capital Acquisition Corp. (IVAN). Honda agreed to join industry leaders General Motors, Hyundai Motor Company, Geely Holding Group, SAIC Motor and Foxconn as the sixth major international car manufacturer to invest in the combined company. Immediately following the business combination, PIPE proceeds are expected to total $275M and Honda will be the largest single PIPE investor owning approximately 2% of the outstanding shares of the combined company.

08:13 EST Aemetis to present at Credit Suisse Energy Summit - Aemetis announced that Chairman and CEO Eric McAfee will provide an overview of the Aemetis Dairy RNG, Aviation Fuel, Renewable Diesel, Ethanol and Carbon Sequestration businesses at the 27th Annual Credit Suisse Energy Summit which will be held at the Grand Hyatt Vail in Vail, Colorado on February 28, 2022. McAfee will present on the topic "$5 billion of New Contracts for Aemetis Carbon Zero Renewable Fuels: Sustainable Aviation Fuel, Renewable Diesel, Dairy RNG, Ethanol, Biodiesel, CO2 Sequestration." The Aemetis Carbon Zero, 90 million gallons per year, renewable jet/diesel fuel plant is currently completing engineering and permitting for the 125-acre Riverbank, California site. Aemetis is also constructing a 52-site Dairy Renewable Natural Gas project near Modesto, California. Phase 1 of the RNG project with two dairy digesters and a 4 mile pipeline is completed and operational. Phase 2 of the project is under construction, including a biogas upgrading facility to produce RNG, a PG&E utility gas pipeline interconnect, 15 additional dairy digesters, and 32 miles of pipeline. The Aemetis Biogas Central Dairy Digester project has already obtained a negative 426 carbon intensity rating from the California Air Resources Board for biogas produced by Phase I. When fully built out, the planned 52 dairy digesters in the Aemetis biogas project are expected to capture more than 1.4 million MMBtu of dairy methane and reduce greenhouse gas emissions equivalent to an estimated 5.2 million metric tonnes of CO2 each year, equal to removing the emissions from approximately 1.1 million cars per year. The Aemetis Biogas dairy RNG project, energy efficiency upgrades to the Aemetis Keyes biofuels plant, and the Aemetis Renewable Jet/Diesel project include $57 million of grant funding and other support from the US Department of Agriculture, the US Forest Service, the California Energy Commission, the California Department of Food and Agriculture, CAEATFA, and Pacific Gas and Electric's energy efficiency program.

08:11 EST E-Home Household Service develops cleaning robot equipment leasing business - E-Home Household Service announced that the company has set up a cleaning robot equipment leasing department in the cleaning service sector, highlighting to promote the growth of the Company's cleaning service business. Wenshan Xie, Chairman and CEO of E-Home, commented: "the Company decided at the recent 2022 business strategy meeting to set up a cleaning robot equipment leasing department. The new business segment will greatly reduce the operating cost of the cleaning department of the Company and improve the profit margin. In addition, with the support of high-tech robot equipment, it will also bring customers a brand new consumption experience, encourage and guide them to spread good corporate reputation information, so as to obtain a continuous competitive advantage in the industry. The new business is expected to contribute approximately $15M in revenue and approximately $3M in net income to the Company in 2022."

08:10 EST LifeMD remains on track to achieve adjusted EBITDA profitability in 4Q22 - LifeMD CFO Marc Benathen added, "In addition to aggressively growing our revenues, we're achieving excellent progress in continuing to drive sequential improvements in Adjusted EBITDA and meaningfully reducing cash burn. We're also pleased to see the continued strength of our subscription revenue. Thanks to our strong focus on unit economics, we remain on track to achieve Adjusted EBITDA profitability by the fourth quarter of 2022 and believe we have more than ample liquidity to do so while achieving aggressive top-line growth goals."

08:09 EST HCW Biologics CEO to present at PepTalk Conference 2022 - HCW Biologics announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Cambridge Healthtech Institute's 24th Annual PepTalk Conference to be held on January 17-19, 2022. The conference is taking place virtually and in person at the Hilton San Diego Bayfront in San Diego, California. Dr. Wong's presentation entitled, "A Novel Platform to Create Multi-Functional Immunotherapeutics for Cancer," is part of the session for Recombinant Protein Expression and Production: Effective Expression and Production of Unique Bioproducts and takes place on January 19 at 11:15 a.m. PST. His presentation will feature a discussion of the Company's internally developed platform for drug discovery called the TOBI platform. The TOBI platform is a scaffold for the creation of novel multi-functional immunotherapeutics that have the potential to rejuvenate the immune system by reducing the accumulation of senescent cells and suppressing the activity of inflammasomes. Using the TOBI platform, the Company has developed over 30 molecules that are capable of activating and targeting desired immune responses and blocking unwanted immunosuppressive activities. Dr. Wong's presentation will include a discussion of data and conclusions contained in recent papers authored by the Company's scientists that have been published in peer-reviewed journals. The presentation will highlight information contained in a pivotal paper published in Molecular Therapy related to preclinical data from in vivo studies demonstrating the potential of the Company's lead investigational candidate, HCW9218, in eliminating therapy-induced senescence and the unwanted side effects of chemotherapy. This ground-breaking finding revealed the underlying mechanism that HCW9218 enhanced the anti-tumor activities and lessened the side effects of chemotherapies. In addition, Dr. Wong's presentation will include a discussion of another paper published in Molecular Therapy related to preclinical data from in vivo studies demonstrating that HCW9218 exhibited favorable pharmacokinetics and pharmacodynamics as a novel immunostimulant with the ability to simultaneously lessen immunosuppression. Finally, the presentation will discuss some of the information in a paper published in Cancer Immunology Research that looked at HCW Biologics' TOBI discovery platform.

08:07 EST WISeKey announces strategic partnership with Universa Blockchain - WISeKey International announces the signing of a strategic partnership with Universa Blockchain. The agreement includes deep cooperation at the La Linea Gibraltar 4th Industrial Revolution Center of Excellence. It was created following the signing of two Memoranda of Understanding with Mr. Fabian Picardo, Chief Minister of Gibraltar and the Mayor of La Linea de la Concepcion, Mr. Juan Franco, to spearhead innovation in the region. The parties will unite joint efforts in the breakthrough directions of Advanced Air Mobility, Energy sector, Central Bank Digital Currency, Non-fungible tokens and Metaverses that Morgan Stanley predicts an $8 trillion opportunity. The partnership also thrives the ecosystem of cities of the Future: National Blockchain, Digital Passports, Smart City Management, Digital coupons and instant verification of documents based on QR codes, Tokenization and Digital Commodity.

08:04 EST Union Pacific, Schneider partner for intermodal service in 2023 - Union Pacific Railroad is pleased to announce it will be the primary intermodal rail transportation provider in the western U.S. for Schneider effective January 2023. The partnership creates seamless service and reliability between the railroad and Schneider, which provides the critical "first and last miles" of the supply chain.

08:04 EST Immix Biopharma announces IMX-110 Phase 1b/2a interim safety data - Immix Biopharma announced positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. Historically, 43%-67% of patients have completed planned treatment cycles with approved drugs used to treat soft tissue sarcoma, STS. Completion of planned treatment cycles refers to lack of drug-related interruptions. "With standard treatments widely used today, cancer patients face a long list of drug-related debilitating side-effects that cause treatment delays, dose reductions, or dose interruptions due to toxicity, interfering with the ability to treat them effectively," said Ilya Rachman, MD PhD, CEO of ImmixBio. "In this interim clinical trial update, we are thrilled to report that IMX-110 has been well tolerated. We believe that IMX-110 could become a potentially attractive option to improve the patient experience in oncology in the future."

08:03 EST Curaleaf to open two new dispensaries in Florida by the end of January - Curaleaf announced plans to open two new dispensaries in Florida by the end of this month. The expansion will increase the company's retail footprint to 44 dispensaries statewide and 119 across the country. Curaleaf Tampa Bay Mabry, located at 13755 North Dale Mabry Highway, opened on January 15th and Curaleaf Largo, located at 10289 Ulmerton Road, is expected to open later this month, subject to final regulatory approvals. In December, Curaleaf added four additional dispensaries in Stuart, Lady Lake, Wesley Chapel and Miami to continue to expand access to the company's quality products and services.

07:58 EST BHP Group backs FY22 iron ore output 249-259MT, down 2% to up 2% from last year - Backs FY22 Petroleum output view of 99-106 MMBOE, down 4% to up 3% from last year. Sees "low end" for FY22 copper output 1,590-1,760kt, down 3% to up 8% from last year, reflecting "lower production guidance for Pampa Norte".

07:48 EST Draganfly partners with Women and Drones - Draganfly is pleased to announce a partnership with Women And Drones, a global platform for women who are disrupting, innovating and shaping the future of STEM and aviation. Women And Drones is the leading membership organization dedicated to driving excellence in the uncrewed aircraft systems and Advance Air Mobility industry by advocating for female participation in this dynamic segment of the global economy.

07:46 EST Jacobs awarded project management contract with Johns Hopkins Medicine - Jacobs was selected by Johns Hopkins Medicine to provide project management services for the redevelopment of laboratory space on its medical campus in Baltimore, Maryland. Plans are to renovate The Johns Hopkins Hospital's existing Children's Medical and Surgical Center and construct a new 12-story North Tower addition. The CMSC Building, originally built as the home for Johns Hopkins Children's Center, a 200-bed hospital, has been used for research labs and offices since 2012. Construction is estimated to be completed in the summer of 2026.

07:43 EST Healthcare Capital announces special meeting date for Alpha Tau combination - Healthcare Capital announced that on January 12, 2022, the U.S. Securities and Exchange Commission declared effective the Registration Statement on Form F-4 filed by Alpha Tau Medical, which includes a definitive proxy statement/prospectus in connection with HCCC's special meeting of stockholders. At the Special Meeting, stockholders of HCCC will consider the previously announced proposed business combination with Alpha Tau, an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The declaration of effectiveness of the Registration Statement by the SEC and the filing of the definitive proxy statement is an important step in Alpha Tau becoming a publicly traded company, with the goal of being listed on the NASDAQ under the symbol "DRTS" at the close of the Business Combination. HCCC will hold the Special Meeting at 10:00 AM Eastern Time on February 15, 2022, to approve, among other things, the proposed Business Combination.

07:34 EST Vivos increases in several metrics for SleepImage HST - Vivos Therapeutics announced increases across several key metrics for its SleepImage Home Sleep Apnea Tests, HST. In particular, for the three-months ended December 31, 2021, versus the three-months ended December 31, 2020, Vivos reported: an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists; a 5.7 times increase in the number of VIPs administering HSTs; and a 3 times increase in the average number of HSTs being administered per VIP. This performance gain in home sleep testing allowed Vivos to renegotiate its commercial agreement with SleepImage. Under the new revenue model with SleepImage, Vivos will lease out the SleepImage ring recorders to Vivos trained dentists at a fixed price that includes a full month's worth of diagnostic sleep test reports. "We have always believed that the pathway to getting more patients into treatment for OSA begins with an easy, inexpensive and highly accurate diagnostic process, which is precisely what the proprietary SleepImage test delivers," said Kirk Huntsman, Chairman and CEO of Vivos. "When coupled with the telemedicine model we have through our collaboration with Empower Sleep, which allows for the required medical diagnosis of OSA remotely, we believe that a historical barrier to patients obtaining a clear and medically valid sleep test report has now been eliminated. The number of positive OSA tests we are seeing is staggering, demonstrating the potential that is available for our Vivos System treatment for OSA. Having now familiarized our VIPs with the prevalence of OSA and giving them a way to test for OSA, our goal will be to use this data to continue to encourage VIPs to get their patients who test positive for OSA into treatment with the Vivos System. Converting positive OSA tests using our HSTs into Vivos System case starts is a major focus of our Practice Advisors and support personnel at Vivos as we roll into 2022. We also expect that our new pricing arrangement with SleepImage will yield positive financial results for Vivos."

07:33 EST Great Panther Mining sees 2022 consolidated gold eq. production 100K-119K oz. - In 2022, consolidated gold equivalent production from the Tucano and Topia mines is expected to be in the range of 100,000 to 119,000 Au eq oz. H2 2022 is expected to account for at least 65% of annual production guidance. The company has budgeted $6M for exploration in 2022, which will be focused on the continued exploration of the company's district-scale land package in Brazil, the majority of which will come in the second half of 2022. Total capital expenditures are budgeted at $22M in 2022.

07:32 EST InMed Pharmaceuticals launches CBT, expanding rare cannabinoid portfolio - InMed Pharmaceuticals announces it has launched B2B sales of the rare cannabinoid cannabicitran, CBT, into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022. InMed's subsidiary, BayMedica, has received initial purchase orders and has commenced commercial sales of the ultra-rare cannabinoid CBT. Additionally, commercial scale production of cannabidivarin is underway, with tetrahydrocannabivarin production scheduled to follow shortly thereafter. The Company expects to produce over 100kg of CBDV and THCV in the coming months to meet anticipated initial demand. "We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors," stated Shane Johnson, SVP and General Manager of BayMedica. "The launch of CBT further demonstrates our ability to produce rare cannabinoids at commercial scale, an achievement that very few companies have been able to accomplish."

07:31 EST ArcBest announces $25M investment in Phantom Auto - ArcBest announced it has invested $25M in Phantom Auto, a provider of human-centered remote operation software. As part of the company's agreement to be the lead investor of Phantom Auto's Series B Preferred offering, Michael Newcity, ArcBest Chief Innovation Officer and President of ArcBest Technologies, will join the Phantom Auto Board of Directors.

07:30 EST Bank of America sees FY22 noninterest expense to approximate that of FY21 - 1Q22 expenses are expected to include seasonally elevated personnel costs of approximately $400M, Bank of America said in slides that will be presented on the Q4 earnings conference call.

07:19 EST Digital asset platform Bakkt teams with Nexo to custody cryptocurrency assets - Bakkt Holdings (BKKT) announced a partnership with leading regulated digital assets institution Nexo, to custody cryptocurrency assets in the Bakkt Warehouse, the company's regulated custodian, which allows for safe and secure storage of bitcoin ($BTC) and Ethereum ($ETH) . "The cryptocurrency market continues to expand at a robust pace, leading reputable crypto companies to diversify custody of assets. We are pleased that Nexo has chosen the Bakkt Warehouse as a trusted solution," said Dan O'Prey, Chief Product Officer, Crypto at Bakkt. "As we build upon our partnerships with businesses and expand our network of operations and revenue, secure custody continues to be a pillar of Bakkt's strategy, leveraging state-of-the-art physical and cyber security, institutional grade technology and governance, and backed by insurance." The Fly notes that Coinbase (COIN) is in the crypto platform group.

07:15 EST Essa Pharma doses first patient in Phase 1/2 trial of prostate cancer candidate - Essa Pharma dosed the first patient in the company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas Pharma's and Pfizer's ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer. This Phase 1/2 trial marks the first of a series of clinical studies to evaluate EPI-7386 in combination with current antiandrogen therapies in patients with mCRPC, with additional Phase 1/2 combination trials anticipated to begin in 2022. The goal of the phase 1 portion of the study is to evaluate the safety and tolerability of the drug combination and establish the recommended phase 2 doses for EPI-7386 and enzalutamide when dosed in combination. The goal of the phase 2 part of the study is to evaluate the safety, tolerability and antitumor activity of EPI-7386 in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent. EPI-7386 is an investigational, highly-selective, oral, small molecule inhibitor of the N-terminal domain of the androgen receptor. The FDA has granted Fast Track designation to EPI-7386 for the treatment of adult male patients with mCRPC resistant to standard-of-care treatment. ESSA retains all rights to EPI-7386 worldwide.

07:14 EST Barrick sees FY21 gold production 4.44M ounces, copper production 415M pounds - Barrick Gold announced preliminary full year and fourth quarter 2021 production results, which demonstrate that despite the ongoing challenges posed by the Covid-19 pandemic, it has met its annual guidance targets for the third consecutive year. Preliminary gold production for the full year of 4.44M ounces was within the 4.4M-4.7M ounce guidance range, with both the Africa & Middle East and Latin America & Asia Pacific regions finishing the year at the higher end of their regional gold guidance range. Preliminary copper production of 415M pounds for 2021 was also within the guidance range of 410M-460M pounds. The preliminary Q4 results show sales for the quarter of 1.23M ounces of gold and 113M pounds of copper, as well as preliminary Q4 production of 1.20 million ounces of gold and 126 million pounds of copper. The average market price for gold in Q4 was $1,795 per ounce, while the average market price for copper was $4.40 per pound. Preliminary Q4 gold production was higher than Q3 2021, mainly due to the strong performance from Carlin and Cortez following the repair of the Goldstrike roaster. Preliminary Q4 gold sales were higher than Q3 2021 as Veladero sold a portion of its built-up gold inventory. Q4 gold cost of sales per ounce are expected to be 3-5% lower than Q3 2021, total cash costs per ounce are expected to be 1-3% lower than the prior quarter, and gold all-in sustaining costs per ounce3 are expected to be 4-6% lower, than in Q3 2021. Preliminary Q4 copper production was higher than Q3 2021, primarily due to increased throughput levels at Lumwana. Preliminary Q4 copper sales were lower than production, mainly due to the timing of shipments at Lumwana. Q4 copper cost of sales per pound is expected to be 13-15% lower and Q4 copper C1 cash costs per pound3 are expected to be 11-13% lower, while copper all-in sustaining costs per pound are expected to be 11-13% higher than Q3 2021 due to higher capital expenditures at Lumwana, primarily related to new mining equipment and stripping.

07:12 EST Procter & Gamble says Q2 gross margin decreased 400 bps versus a year ago - Gross margin for the quarter decreased 400 basis points versus year ago, 410 basis points on a currency-neutral basis. Reductions in gross margin were driven by 400 basis points of higher commodity costs, 140 basis points driven by negative product mix, 60 basis points from increased freight costs, and 20 basis points of product/package reinvestments. These were partially offset by 130 basis points of benefit from increased pricing and 80 basis points of gross productivity savings. Selling, general and administrative expense as a percentage of sales decreased 150 basis points versus the prior year, 170 basis points on a currency-neutral basis. The decrease was driven by 150 basis points of cost leverage benefit from increased sales and 70 basis points of gross productivity savings from overhead and marketing expenses, partially offset by 50 basis points of marketing spending and overhead investments net of other impacts. Operating margin for the quarter decreased 250 basis points versus the prior year, 240 basis points on a currency-neutral basis. Operating margin included gross productivity cost savings of 150 basis points. "We delivered very strong top-line growth and made sequential progress on earnings in the face of significant cost headwinds," said Jon Moeller, President and CEO. "These results keep us on track to deliver our earnings outlook and to raise estimates for sales growth, cash productivity and cash return to shareowners. Our focus remains on the strategies of superiority, productivity, constructive disruption and continually improving P&G's organization structure and culture. These strategies have enabled us to build and sustain strong momentum. They remain the right strategies to deliver balanced growth and value creation."

07:10 EST DarioHealth signs agremement with regional health plan - DarioHealth has contracted with a large regional health plan to deliver its digital therapeutic solution for diabetes for eligible Medicaid members in and around the mid-Atlantic region. The contract is expected to contribute to revenue beginning in Q2.

07:09 EST Ginkgo Bioworks acquires Project Beacon COVID-19 LLC, terms not disclosed - Ginkgo Bioworks announced the acquisition of Project Beacon COVID-19 LLC, a Boston-based social benefit organization focused on helping to increase the capacity, availability, accessibility and affordability of COVID-19 testing. Under the terms of the deal, Ginkgo acquired Project Beacon's assets and will assume responsibility for Project Beacon's ongoing operations, providing COVID-19 monitoring tools to communities in Massachusetts and other areas.

07:08 EST Next Hydrogen Solutions announces collaboration with Black & Veatch - Next Hydrogen Solutions is pleased to announce that it has been selected by Black & Veatch to participate in their IgniteX Climate Tech Accelerator program. This program will allow Next Hydrogen and Black & Veatch to collaborate on the development of green hydrogen solutions that have the potential to significantly decarbonize the industrial and transportation industries. Next Hydrogen was selected among nearly 100 companies to participate in the program, which provides funding and support to companies on the cutting edge of climate technology. Together, Black & Veatch and Next Hydrogen will develop engineered solutions for the production of green hydrogen in industrial uses such as ammonia, steel and cement, and transportation applications such as heavy mobility and off-highway fleets. Next Hydrogen's unique hydrogen technology expertise and Black & Veatch's vast network and engineering leadership will offer an integrated hydrogen solution to clients worldwide to help them achieve their decarbonisation and ESG initiatives.

07:07 EST Compass Pathways announces results from survey conducted with Sermo on TRD - COMPASS Pathways and Sermo announced findings from a survey of Sermo physician members that showed two thirds of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression, TRD. The survey of 259 Sermo member physicians, sponsored by COMPASS, was conducted in November 2021 and completed by participants from the US, the UK, France, Italy, Denmark, Spain and the Netherlands. Doctors were asked their views on the future of psychiatric therapy and the potential role of psilocybin therapy. Key survey findings: 66% of doctors surveyed believe psilocybin therapy has potential benefit for patients with TRD; 50% would prescribe psilocybin therapy, if it was approved; 32% are undecided; The greatest potential advantages to psilocybin treatment are believed to be: improved efficacy in treatment-resistant conditions, rapid onset of action, and different mechanism of action from existing therapies; The greatest potential barriers to treatment were cited as: needing a dedicated space for six to eight hours, lack of trained therapists in a new model of psychological support, and office infrastructure; Opinions on the optimal setting for psilocybin administration varied by region: 50% of European respondents said hospital; 42% of US respondents said specialized network of centers.

07:07 EST ADMA Biologics says strategic review is ongoing - As previously disclosed, ADMA has engaged Morgan Stanley as an advisor to evaluate a variety of strategic and financing alternatives. The evaluation of these alternatives as well as the formal engagement with Morgan Stanley demonstrate ADMA's management and Board of Directors' unwavering commitment to creating value for its stockholders. Further, ADMA continues to actively engage prospective debt lenders to potentially refinance and expand ADMA's current debt facility. These concurrent processes are ongoing, and the Company will communicate developments as they unfold and as required by the Securities and Exchange Commission.

07:07 EST Orthofix teams with imaging and guidance systems firm nView medical - Orthofix Medical and nView medical, a Salt Lake City-based company developing surgical imaging and guidance systems enabled by artificial intelligence announced a partnership and investment agreement to jointly develop and co-market the innovative nView systems with Orthofix cervical spine and pediatric limb deformity correction procedural solutions. The novel nView s1 system with insta-3D technology is a U.S. Food and Drug Administration 510 k cleared imaging system that features the unique ability to instantly capture 3D images with very low-dose radiation. This approach makes the 3D images available throughout surgery, enabling real time visualization. The nView s1 doubles up as a surgical guidance system with GPS-like technology that uses the true representation of the anatomy as maps and incorporates AI technology to augment the surgeon's understanding of the surgery. As part of the collaboration, Orthofix will utilize an nView s1 imaging and navigation system in its Lewisville, Texas training facility where they will conduct joint educational programs for surgeon customers. Orthofix and nView medical will work together to gain 510 clearances for Orthofix pediatric limb deformity solutions navigated with the nView s1 system. Additionally, the companies will pursue the development of an application of the technology for adult cervical spine procedures utilizing Orthofix's comprehensive portfolio of cervical solutions.

07:06 EST ADMA on track to have 10 or more plasma collection centers by end of 2023 - ADMA currently has nine plasma collection facilities under its corporate umbrella at various stages of FDA approval and development, including six facilities that are currently operational and collecting plasma. The Company remains on track to have 10 or more plasma collection centers FDA-licensed by year-end 2023. The anticipated yield enhancement resulting from the recent Haemonetics Persona implementation, in combination with the Company's growing BioCenters network, has ADMA well-positioned to achieve source plasma self-sufficiency by year end 2023 and contribute to quarter-over-quarter revenue and plasma collections growth throughout 2022 and beyond. We believe these activities will help ensure continuity of commercial product supply to customers and patients in the growing U.S. IG market.

07:05 EST Procter & Gamble sees FY22 capital spending 4%-5% of FY22 net sales - P&G continues to estimate a core effective tax rate in the range of 18% to 19% in fiscal 2022. P&G increased its outlook for adjusted free cash flow productivity to 95% and now expects to pay over $8B in dividends and repurchase $9B-$10B of common shares in fiscal 2022. Combined, P&G now plans to return $17B-$18B of cash to shareowners in the fiscal year.

07:04 EST Adagene expands the SAB with appointment of Gandara - Adagene announced the appointment of David Gandara, M.D., to its Scientific and Strategic Advisory Board, the SAB. Dr. Gandara, Professor Emeritus and Senior Advisor of the Thoracic Oncology Program at University of California Davis Comprehensive Cancer Center, brings "knowledge and understanding to the immuno-oncology field," the company said.

07:03 EST Gamida Cell to initiate rolling BLA submission for omidubicel - Gamida Cell announced that following receipt of positive Type B meeting correspondence from the FDA yesterday, the company plans to initiate a rolling biologics license application, or BLA, submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant. As previously disclosed, in late 2021 the FDA requested a revised analysis of the manufacturing data generated at Gamida Cell's wholly owned commercial manufacturing facility to demonstrate the analytical comparability to the Lonza clinical manufacturing site that produced omidubicel for the Phase 3 study. Gamida Cell and the FDA have now reached alignment that analytical comparability has been established between the commercial manufacturing facility and the product that was manufactured for the Phase 3 study. Based on this demonstration of comparability, along with the clinical results of the Phase 3 study, the FDA has agreed that the initiation of a rolling BLA submission is appropriate. Additional clinical data will not be required to initiate the BLA submission.

06:54 EST Osmotica Pharmaceuticals changes name to RVL Pharmaceuticals - Osmotica Pharmaceuticals (OSMT) announced that the company has changed its name to RVL Pharmaceuticals (RVLP). This rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics, and, as part of this transformation, RVL has launched a new corporate website www.rvlpharma.com.

06:48 EST Bank of America CEO: Investment banking had its best year ever - Chairman and CEO Brian Moynihan said: "Our fourth-quarter results were driven by strong organic growth, record levels of digital engagement, and an improving economy. We grew loans by $51 billion and added $100 billion of deposits during the quarter, further strengthening our position as the leader in retail deposits. We earned a record $32 billion in 2021, with every business line solidly contributing. In Consumer, we added millions of new credit card accounts and nearly a million net new checking accounts as we continued to demonstrate the value we provide through our physical and digital capabilities. Wealth Management had record client flows and the strongest client acquisition numbers since before the pandemic. Investment Banking had its best year ever and Global Markets had its highest sales and trading revenue in a decade, led by record Equities performance as we invested in the business."

06:47 EST Bank of America reports Q4 net interest income $11.4B, noninterest income $10.7B - Provision for credit losses improved by $542 million to a benefit of $489 million. Noninterest expense rose 6% to $14.7 billion, driven by higher revenue-related incentive compensation, partially offset by lower COVID-19 related costs. Average loan and lease balances up $10 billion to $945 billion. Average deposits up $280 billion, or 16%, to $2.0 trillion. Common equity tier 1 ratio 10.6%.

06:45 EST Bank of America reports Q4 trading revenue ex. DVA $2.93B

06:33 EST Gold Resource sold 22,644 ounces of gold and 1,066,581 ounces of silver in 2021 - Gold Resource sold a total of 22,644 ounces of gold and 1,066,581 ounces of silver in 2021 for a gold equivalent total of 37,512 ounces. Additionally, the company sold 13,553 tonnes of zinc, 1,420 tonnes of copper and 5,999 tonnes of lead resulting in a year-end cash balance of $34M. Fourth Quarter 2021 Production Highlights: 9,848 gold equivalent ounces sold, inclusive of 6,119 gold ounces and 287,805 silver ounces sold; 405 tonnes of payable copper; 2,059 tonnes of payable lead; 4,167 tonnes of payable zinc. Allen Palmiere, President and CEO, said, "As I reflect on my first year at Gold Resource Corporation, I am pleased with the results of the Don David Gold Mine and the acquisition of Aquila Resources Corporation. Despite ground control challenges and the voluntary temporary shutdown due to COVID-19 in late August and early September, our Mexican operation still achieved the high end of guidance for gold production. Throughout the year, the team took a disciplined approach to identifying opportunities for improvements and implementing efficiencies. Our exploration investment has shown great promise and has given us excellent targets for our 2022 in-mine and near mine drill program. In addition, the completion of the filtration plant and dry stack facilities advances our environmental stewardship efforts. I am optimistic about 2022 as we continue to plan for our future in Oaxaca and advance the definitive feasibility study for the Back Forty Project in Michigan."

06:24 EST Fulton Financial sees FY22 net interest income $660M-$680M - Sees FY22 noninterest income $230M-$245M, with noninterest expense $580M-$600M. Sees FY22 effective tax rate 16.5%-17.5%. Comments taken from Q4 earnings conference call presentation slides.

06:09 EST Exscientia appoints Charlotte Deane as Chief Scientist of Biologics AI - Exscientia has appointed Charlotte Deane as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence, machine learning, and the design of protein structures in the discovery and development of novel drug candidates. Deane joins Exscientia's technology leadership team, reporting to Chief Technology Officer, Garry Pairaudeau. Deane has held numerous senior roles at the University of Oxford, where she is currently Professor of Structural Bioinformatics and leads the University's Protein Informatics group. She will maintain both of these roles. Prior to this, she was Deputy Executive Chair of the Engineering and Physical Sciences Research Council at UK Research and Innovation. During the COVID-19 pandemic she was the UKRI's COVID Response Director, and was a member of SAGE, the UK Government's Scientific Advisory Group for Emergencies.

06:06 EST Pan American Silver reports preliminary Q4 silver production 5.28M ounces - Reports preliminary Q4 gold production 156,700 ounces. The company said, "Pan American Silver is currently experiencing the effects of the latest wave of COVID-19 infections, which has led to reduced workforce levels. At the present time, it is too early to determine what impact, if any, the current COVID-19 situation may have on operations in the first quarter or full-year 2022. Consequently, Pan American Silver has decided to postpone issuing its 2022 production and costs guidance. We intend to provide 2022 guidance no later than February 23, 2022, when Pan American Silver releases its audited results for Q4 and FY 2021."

06:05 EST Pan American Silver reports preliminary FY21 silver production 19.2M ounces - Pan American Silver announced its preliminary production results for FY21. Consolidated silver production in 2021 of 19.2M ounces was within the revised guidance range of 19M to 20M ounces provided on November 9, 2021. Consolidated gold production in 2021 of 579.3 thousand ounces was within the revised guidance range of 560,000 to 588,000 ounces provided on November 9, 2021. Dolores achieved record gold production of 160,100 ounces in 2021. "Production improved in 2021 over 2020, although continued to be constrained by reduced workforce deployment levels due to the COVID-19 pandemic. We are pleased to see progressive production ramp up at La Colorada during the fourth quarter of 2021, following the advances on the upgrades to the ventilation circuit and ground support programs," said Michael Steinmann, president and CEO.

06:02 EST Babylon Holdings acquires DayToDay Health - Babylon completed its acquisition of DayToDay Health to provide Babylon members with DayToDay's digital-firs programs and clinical services prior to and following scheduled surgeries, major health events like childbirth, and following diagnosis of chronic conditions. DayToDay provides patients targeted education, communication and clinical support from a personal care team before or after clinical visits, hospitalizations, or surgeries. Babylon will integrate DayToDay's scalable capabilities into its existing digital-first healthcare offering. Headquartered in Boston, DayToDay was founded in 2018 by a team of engineers, scientists and clinicians during their time at MIT with the goal of managing virtual patient care - specifically acute, post-surgical, and out-of-hospital care.

05:39 EST BIT Mining Limited provides update on Ohio mining site - BIT Mining Limited announced its progress in the construction and buildout of its Ohio mining site in North America. In collaboration with its partner, the company has achieved approximately 50 megawatts of power capacity at the Ohio mining site. As announced in October 2021, BIT Mining is constructing a data center in Ohio with a total planned power capacity of up to 150MW. As the data center's power capacity continues to scale, the company is not only conducting self-mining operations, but is also hosting third-party miners. Xianfeng Yang, CEO of BIT Mining, commented, "Our Ohio Mining Site continues to grow, and we are making progress in its buildout and in securing mining machines, despite ongoing industrywide supply-side constraints. 50MW is our first notable milestone, but this is only the beginning. We intend to reach our goals of extending our footprint and creating strong industry partnerships. As we continue to grow our computing power, we are also focused on creating a technology-driven diversified enterprise, capable of generating revenue along the cryptocurrency value chain."

05:28 EST UCB to acquire Zogenix for $26 per share, milestone-based CVR - UCB and Zogenix announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix. Under the terms of the agreement, UCB will commence a tender offer to purchase all outstanding shares of Zogenix for a purchase price per share of $ 26.00 in cash at closing, plus a contingent value right, or CVR, for a potential cash payment of $2.00 upon EU approval by December 31, 2023, of Fintepla as an orphan medicine for treatment of Lennox-Gastaut syndrome, or LGS. The upfront consideration represents a 72% premium to Zogenix shares based on the 30-day volume weighted average closing stock price of Zogenix prior to signing. The total transaction is valued at up to approximately $ 1.9B. The board of directors of both companies have unanimously approved the transaction, the closing of which remains subject to the tender of shares representing at least a majority of the total number of Zogenix's outstanding shares, receipt of required antitrust clearances, and other customary conditions. Zogenix has submitted a Type II Variation Application to the EMA, and the U.S. FDA recently accepted for filing Zogenix's supplemental New Drug Application, granting Priority Review, for LGS. Under the terms of the acquisition agreement, UCB, through a wholly-owned subsidiary, Zinc Merger Sub, will initiate a tender offer to acquire all outstanding shares of Zogenix for a purchase price of $26.00 per share in cash, plus one non-tradeable CVR. The CVR will entitle holders to an additional cash payment of $2.00 per share if a regulatory milestone related to approval of Fintepla for treatment of seizures associated with Lennox-Gastaut syndrome is achieved by or before December 31, 2023. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Zogenix's outstanding shares, receipt of required antitrust clearances, and other customary conditions. Upon the successful completion of the tender offer, UCB's acquisition subsidiary will be merged into Zogenix, and any remaining shares of common stock of Zogenix will be cancelled and converted into the right to receive the same consideration per share offered in the tender offer. The transaction is expected to close by the end of the second quarter of 2022. There can be no assurance any payments will be made with respect to the CVR.

05:19 EST Smith & Nephew acquires Engage Surgical for $135M - Smith+Nephew announced the acquisition of Engage Surgical, owner of the only cementless unicompartmental knee system commercially available in the U.S. The Engage Surgical Partial Knee System is a modern cementless knee implant to serve a resurgent segment driven by the potential for better long-term fixation through biologic integration, shorter operating times, and the shift to Ambulatory Surgery Centers. With Engage Surgical's Partial Knee System, Smith+Nephew expects to be able to drive market expansion in the U.S., and in time in other markets as regulatory approvals are secured. Engage Surgical's Partial Knee System currently has regulatory clearance in the U.S. where it is in limited market release. The cost of the acquisition is up to $135M contingent on sales performance. The acquisition was financed from existing cash and debt facilities. Engage Surgical is located in Orlando, Florida.

05:12 EST B2Gold sees FY22 gold production 990,000-1,050,000 ounces - B2Gold announced its production and budget guidance for 2022. For 2022, B2Gold reports total gold production guidance of between 990,000-1,050,000 ounces with total consolidated forecast cash operating costs of between $620-$660 per ounce and total consolidated AISC of between $1,010-$1,050 per ounce; consolidated cash operating costs per ounce and AISC per ounce are forecast to be higher than 2021 mainly due to higher budgeted prices for fuel, labor and other consumables and a stronger budgeted Namibian dollar while the increase in AISC per ounce is also impacted by moderately higher planned sustaining capital expenditures Due to the timing of high-grade ore mining, consolidated gold production from the company's three operating mines is expected to be significantly weighted to the second half of 2022; for the first half of 2022, consolidated gold production is forecast to be between 390,000-410,000 ounces, which is expected to increase significantly to between 560,000-590,000 ounces during the second half of 2022. B2Gold is planning a year of aggressive exploration in 2022 with a budget of approximately $65M, including a record $29M allocated to the company's ongoing grassroots exploration programs. Based on current assumptions, including a gold price of $1,800 per ounce, the company expects to generate cashflows from operating activities of approximately $625M in 2022, expected to be significantly weighted to the second half of 2022.